var title_f19_31_19952="Digital clubbing";
var content_f19_31_19952=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Digital clubbing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_31_19952=[""].join("\n");
var outline_f19_31_19952=null;
var title_f19_31_19953="Esophageal dilation after gastric banding";
var content_f19_31_19953=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F52070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F52070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal dilation after gastric banding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 430px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The esophagram demonstrates the appearance of esophageal dilation from a gastric band that is too tight.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_31_19953=[""].join("\n");
var outline_f19_31_19953=null;
var title_f19_31_19954="Patient information: H. pylori infection (The Basics)";
var content_f19_31_19954=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15734\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/54/40804\">",
"         Organs inside the abdomen (belly)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/53/19281\">",
"         Patient information: Anemia caused by low iron (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/57/28562\">",
"         Patient information: Nausea and vomiting in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/53/5971\">",
"         Patient information: Peptic ulcers (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/58/14242\">",
"         Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/60/964\">",
"         Patient information: Peptic ulcer disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: H. pylori infection (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/h-pylori-infection-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1480480751\">",
"      <span class=\"h1\">",
"       What is H. pylori infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;H. pylori infection is a condition that can sometimes cause pain in the upper belly, bloating, nausea, or vomiting.",
"     </p>",
"     <p>",
"      H. pylori infection occurs when a type of bacteria called H. pylori infects a person&rsquo;s stomach or duodenum. The duodenum is the first part of the small intestine (",
"      <a class=\"graphic graphic_figure graphicRef64960 \" href=\"UTD.htm?39/54/40804\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Many people have H. pylori infection. Most of the time, H. pylori infection does not lead to any problems or cause any symptoms.",
"     </p>",
"     <p>",
"      But in some people, H. pylori infection leads to problems that can cause symptoms. These problems can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Open sores, which are called &ldquo;ulcers,&rdquo; on the lining of a person&rsquo;s stomach or duodenum",
"       </li>",
"       <li>",
"        Stomach cancer",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Doctors do not know why H. pylori infection leads to problems in some people and not others.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1480480758\">",
"      <span class=\"h1\">",
"       What are the symptoms of H. pylori infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with H. pylori infection have no symptoms. But people who have ulcers can have symptoms that are caused by the ulcers. Common symptoms of ulcers can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain in the upper belly",
"       </li>",
"       <li>",
"        Feeling bloated",
"       </li>",
"       <li>",
"        Feeling full after eating a small amount of food",
"       </li>",
"       <li>",
"        Not feeling hungry",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"       <li>",
"        Dark or black-colored bowel movements",
"       </li>",
"       <li>",
"        Feeling more tired than usual",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Not all ulcers are caused by H. pylori infection. For example, people can get ulcers from taking certain pain-relieving medicines. But if you have the symptoms listed above, let your doctor or nurse know.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1480480765\">",
"      <span class=\"h1\">",
"       Is there a test for H. pylori infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors can do different tests to diagnose H. pylori infection. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Breath tests &ndash; These tests measure substances in a person&rsquo;s breath after he or she has been given a special liquid to drink.",
"       </li>",
"       <li>",
"        Lab tests that check a sample of a bowel movement for H. pylori infection",
"       </li>",
"       <li>",
"        Biopsy &ndash; For this test, a doctor takes a small piece of tissue from the lining of the stomach. Then he or she looks at the tissue under a microscope. A doctor can do a biopsy during a procedure called an endoscopy. An endoscopy is a procedure that lets a doctor look at the inside lining of the esophagus, stomach, and duodenum.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1480480772\">",
"      <span class=\"h1\">",
"       Should I be tested for H. pylori infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should be tested for H. pylori infection if you have symptoms and:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have an ulcer in the stomach or duodenum",
"       </li>",
"       <li>",
"        Have had ulcers in the past",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sometimes, doctors test people who have no symptoms for H. pylori infection if they have a family history of stomach cancer. Doctors also sometimes test people with symptoms who have never had an ulcer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1480480779\">",
"      <span class=\"h1\">",
"       How is H. pylori infection treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;H. pylori infection is treated with medicines. Most people need to take 3 or more medicines for 1 to 2 weeks. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to reduce the amount of acid that the stomach makes &ndash; This can help cure the infection and help ulcers heal.",
"       </li>",
"       <li>",
"        Different types of antibiotics",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People who are diagnosed with H. pylori infection should get treated, because treatment can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Help ulcers heal",
"       </li>",
"       <li>",
"        Prevent ulcers from coming back",
"       </li>",
"       <li>",
"        Reduce the chance that an ulcer will get worse",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      It is important to follow all your doctors&rsquo; instructions about taking your medicines. Let your doctor or nurse know if you have any side effects or problems with your medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1480480786\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, most people have follow-up tests to check that the H. pylori infection has gone away. Follow-up tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Breath tests",
"       </li>",
"       <li>",
"        Lab tests that check a sample of a bowel movement",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Most of the time, H. pylori infection is cured with treatment. But sometimes, H. pylori infection is not cured with treatment. People who still have H. pylori infection after being treated might need to take medicines for another 2 weeks.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1480480793\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=see_link\">",
"       Patient information: Peptic ulcers (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/53/19281?source=see_link\">",
"       Patient information: Anemia caused by low iron (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=see_link\">",
"       Patient information: Nausea and vomiting in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=see_link\">",
"       Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=see_link\">",
"       Patient information: Peptic ulcer disease (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?19/31/19954?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15734 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-FC54B750F8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_31_19954=[""].join("\n");
var outline_f19_31_19954=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1480480751\">",
"      What is H. pylori infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1480480758\">",
"      What are the symptoms of H. pylori infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1480480765\">",
"      Is there a test for H. pylori infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1480480772\">",
"      Should I be tested for H. pylori infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1480480779\">",
"      How is H. pylori infection treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1480480786\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1480480793\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15734\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/54/40804\">",
"      Organs inside the abdomen (belly)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/53/19281?source=related_link\">",
"      Patient information: Anemia caused by low iron (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=related_link\">",
"      Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=related_link\">",
"      Patient information: Nausea and vomiting in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=related_link\">",
"      Patient information: Peptic ulcer disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=related_link\">",
"      Patient information: Peptic ulcers (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_31_19955="Triamcinolone (ophthalmic): Patient drug information";
var content_f19_31_19955=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Triamcinolone (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/55/8052?source=see_link\">",
"     see \"Triamcinolone (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/36/16963?source=see_link\">",
"     see \"Triamcinolone (ophthalmic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9606516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Triesence&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691836",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691299",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used during eye surgery.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to triamcinolone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695993",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the eye.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12328 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-043A92644E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_31_19955=[""].join("\n");
var outline_f19_31_19955=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606516\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024633\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024632\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024636\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024637\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024639\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024635\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024641\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5637?source=related_link\">",
"      Triamcinolone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/10/16548?source=related_link\">",
"      Triamcinolone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/56/16260?source=related_link\">",
"      Triamcinolone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/55/8052?source=related_link\">",
"      Triamcinolone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/36/16963?source=related_link\">",
"      Triamcinolone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31768?source=related_link\">",
"      Triamcinolone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/49/5910?source=related_link\">",
"      Triamcinolone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/11/27831?source=related_link\">",
"      Triamcinolone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/30/32229?source=related_link\">",
"      Triamcinolone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/46/36580?source=related_link\">",
"      Triamcinolone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/10/14500?source=related_link\">",
"      Triamcinolone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_31_19956="Supraperiosteal infiltration";
var content_f19_31_19956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F87573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F87573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 650px\">",
"   <div class=\"ttl\">",
"    Supraperiosteal infiltration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 630px; height: 415px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Nerve supply of the maxillary teeth.",
"    <br/>",
"    (B) Needle insertion at the mucobuccal fold allows deposition of anesthesia close to the tooth apex.",
"    <br/>",
"    (C) Minimal depth of needle insertion (about 2 mm) is required for the anterior primary maxillary teeth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kassuto Z. Orofacial anesthesia techniques. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Ed), Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_31_19956=[""].join("\n");
var outline_f19_31_19956=null;
var title_f19_31_19957="EEG barbiturate effect";
var content_f19_31_19957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F66590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F66590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Effect of short-acting barbiturate on electroencephalogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intravenous administration of the short-acting agent, methohexital (Brevital&reg;), was followed by the appearance of high frequency (beta) activity. Electrical activity at more than 12 Hz is particularly prominent in the frontal, temporal, and parietal regions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahram Khoshbin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_31_19957=[""].join("\n");
var outline_f19_31_19957=null;
var title_f19_31_19958="Binding injured pelvis with sheet";
var content_f19_31_19958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Binding injured pelvis with sheet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 391px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Circumferential pelvic antishock sheeting is applied. The patient's clothing should be removed before application. The sheet is positioned beneath the patient's pelvis, being careful to avoid wrinkles that can create pressure sores. (B) The ends of the sheet are crossed in an overlapping manner anteriorly and (C) are pulled taut. (D) Clamps secure the smooth and snug sheet. The sheet pictured above is longer than that used in some instances; a sheet length limited to the pelvis is suitable.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Routt ML, Falicov A, Woodhouse E, Schildhauer TA. Circumferential pelvic antishock sheeting: a temporary resuscitation aid. J Orthop Trauma 2002; 16:45. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_31_19958=[""].join("\n");
var outline_f19_31_19958=null;
var title_f19_31_19959="Geographic tongue";
var content_f19_31_19959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74654%7EDERM%2F79512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74654%7EDERM%2F79512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Geographic tongue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martha Ann Keels, DDS, PhD, Duke Pediatric Dentistry.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Geographic tongue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCoWKkFSB6mlmdipG5VLdT6U2dSWJTiqdw4jYAltw5x2rmR6NiO7u9oLDgAdexqJr9JIRt3OPQKOtUby6LH9+y7RyFA61jT38kpLecwAOdoAGB61fKaRRvi8dIvM4VWOCpPU1J/aCBSA218ZGe9cdLek9NxBPU9TTBdkjbnI96XIbKC6nU3eqedEEfhgcgiok1AOm12w6njPpXPG5L8MaFnGBxyD1pchsopHQPc7VDITkdee1KLvbIrKflbrWAt0y7skZpwu+Vxwc0chpFvY6QSEqWVhg1bS5X7PtbHIrlEv2TI9akXU9gKtj6mjkG7m9IQi7gx96h+3CM58zkVz91rij7hyelZTai8h5BBNPkJdWK0bO2k1NXAYMKgbU0UHD5P1rjmnlccSYFNUOerZ9s9afs0L6wlokdc2spuHzjioZdcjY8GuYaMEZXP0NJ5R79TT9mg9vK9kjpn1gTRgB8AUf2nEVA31z9vGdjAdQOPekC/WjlQOq+qOgOqKGA3Vct79G4LD6ZrkiMc03c3ZiKfIS6vkd7DdRk4BFXYJot25mGPrXnK3My8BzxUgvZ8YMhpchPtIvc9Je4hAz5gqrLqkCKfmzXAG6nPR2xTRI7SYdzzxT5CuaJ2Nxr0UYwpH51jXWssZC0ecmsgxPnJ5HrTH4yKagHtGtjSOszk5Gc1BdahPcYLORiqaqxP3TTtjDqpo5CfaMsLeT/32/OmtdTZz5hzTVVsn5Se3SrNvZySNnaTjsKfIHO+5Wurm4SJPnbJ9aYk80kYIYnFTain7wR8Er1PvVdFZeVqLpGijUbuWI3cD5ySfTNKZ5F7nnim+ZKFIBAB64FRiNj/AProujRUpjjcyKeeakS/lU/cFRrCT0FWIbJ5WAVSSfalc0jQl1Y1b9ud4PNSLqGw5CnNK+mzIcGNs+4qMWcjZwjHHoKm5qqLJDqcueM0kWoEN86FhnPWp7fSLqY4SFz/AMBrRi8L3rMAYsAnGc0DdNLdmU1+xO5Yxj600Xr7s7D9M11Ft4MuGZN7qu44IHNaX/CFRRyPHI77v4cCnaQXprS5wpuXY8Lg0wzSHjBz1r0y28KWJjUSW7YQ4L56/Wrf/CN6ehKCGPf/AA4GefrRysXtKa6Hk++UDpxSD7QxChXPsAa9WTQoIHbbFFJj1X1qwthFHkxxrvC9hyKfKZyqLojx8SSK43Kdy8mtG31Ao5aIkFuTH1Fd3d6PDPOZBGoJGCNuRVabwxYzFshlduhQ4xRymMpR2aMu2uUdVSIKzKAXcHge31rYiG6NXlkGB0Fcvf6bJo0/7ws9u3yq/ofetrTvLKCRWDZrKSOecLao24nIwYMEEZ5HH5VYDl8BDjsTVGFXBDIxA/IVbQKrEZw2OgFSY21K7FlHIJ96o3DqZA3XA5Fa9xGNnUjFZcqsMny96noapOxCVznL5DJ5nygPngjsK5u/Vo+Ox5J9a7a5hRomAYAnqCOa5PWI/s8bliACDz6itYO5tFaGBdX0NtxK+D2AGarDWrYnhZD+Fc9cOZZXcknJ4zVywsZJwGAwnqa6vZxiryOVV5ylaJuJrFu2ABJn6VOL9COEkx9KoW2n7XywrQEWBnFYyceh1wdVogm1NkjPlwkn3NV11C8YAkIPXjpVxoQw5FOSAAdBT5klsLlqydrkCXFy/DnH0FPCM33mY59asrD3xUiRMR0qXI0jh5P4iqIsdqesfSr0dnK5GEJB4BrodI8I6he3Cp5fygbm56CpuX7GENZM5ZIBjkc1J9nwOQa9Os/BUKKrO25ycFPStJfCVtZSGa4tzIoHyow4bI7kUtTSMqK6HkJt8Yx1pfKJ7fjXqqeHrLy4Ea2RthJYoPmJz0J7irMvhWzCfaUt1W2ZvL+brnvx14p2bNFUpLoeRRxlHGQSQelWxaCc5QjNerDQrRTGY4Y5IFDIquRuA7k/jUlr4Y06VXEsJjBTKkLnOD39PrVJNGVSUJ62seRSaZccjZnA9agexlQDepAPfNewXfhOxUFQirHHJtIB5P1NZ9x4SsZY5CN0JCfuyCSHI79OKrmfYyUYbtnlhtlUHc2TjtTPJQHKsfwFegz+B5vOCxSIwZQQRzmqL+D7z5QiqWPUDt9alyl2N40qPc44Db9zn3IpmDv3H72c5rrZfCF8j7HjKHGRv4Bx6Gm2HhW7uZwp+Ve7MOlK7L5Ka6nNBnJztGaELg8Ip/CvTbHwZFb7ftCxyZ53A/pVyLQbPdgW4DMQNrDG4fjT94i9Ltc8tjMp5EKc+i1aiN7JhIrVXJ4GIyTmvUYNGto0GIk2Z7jofSrU1lHCzKixqFCjMQI3Y53UWfclyj0ieTxx3wmMZt8OpIKtHyCO1XPsGsSKsO1o1kG7AAAxXpMNio3O4LO5LMepb8fWrCwqI/KUKI8humW9uaLeZaa6RR5Snhm+PLREL1zircPhC7kYKCmTyM+leleWxGG+Yr6jp65pPKTJUYC/Tmlyo2VSZwlt4PUriefa5bBwOAK0LbwharzKWwT8rdRXYtGvP3MYxkCnMgjOABvGDlT0osiHOb0ucx/wi1ohYBFdEP3um73rb0jSNOhhdbiMxSL80R253e1aDxbY0lXZsZyAC2SMeopBGSJCQuOCQRnFOxLTmrXL9zomlLI/2eUXMcq7VGza2/6HkD3rPk0O1t2uBcJ9mnRAFiABDfU1ZtWYyQuQJCvHI/zmpr6FGDvhgWOFx0GeoxQZqEouzZixWiKAwQAdOmKkkjGchMAfwipyGBP3QRxgjg0qKIriKV0V1RgSuSA49KDZwI2t3gdDKhXP4GrMcMhD7wHCjcCW5FSXUxvbp5RHttw+REp3FR2Ge9GVEKN5BCRNhpByTnnBFAKOiImAClZZDgjoo4PsaQxx/cRsITuBxyPaprzUkS0+xwxxNbmXzRMUw/I6fSqRbA+dsZ/SkVGm7XaFlQuCWY7gfm4wag+6BkgNj5SO4pz3APJznoT6io0lDsy5GR0zRcHBohcbACDtwaeyZHOAw5/3qJF3DgnjtQznygpP3PzoTM5RKNzFFc28kN1GGDdOK5WxjFtfyQEZCHhvauuutqIWduB3rkpbvyfEnloQQ6ZI/Gs5aowkrM6GFC4Gc47YHWre07hv4wOCRzTrYkplO4xwKsNbsOrLnt3rJmFtSKUZyriqjW5GcE7fSrrNvxjBxT1kZQUIBB9qZKRhXFqsgPGB3964PxtB5Vu3lAnKkYPavWJYI2Q8kt6CuL8cWyCyIVBuPpVwdmV5Hkeg6BPq11sQYjHU16FB4WEduFU8qOmK0PBFnHHa7toDZ5ruo4Y5Iw2FGO2K6pzciKMfZ/CeZjw6/ckY5q5baFaywkHdv3YzXW3aKrMVHNRW9sqQmaUEs3QelZaHW5yaucxF4ZV5jydg6e9Wl8L25B3Fgcc+ldXaKJOIlXzCO/RfrUs9g1sPMlk3Keme59hRoClK9rnJR+GIFYAg88c/0rRsdCt4iV2JIvqetakhjjC7sgngAn9acOfl4GfTv9aE0Nxm3qRQQRRSrFBArliQseOAfUV2elaedPtFEwXcRtxnge9Z2i6UYbkT3EjJIg3KMZHtitZ/mUu6s2SRknjNO9jmmlJ8qC0tjcXzldrgdDtwAfpVm4aW8smIRCM7Au7bz6mo7e0mNo0sEyIR8wVurc9qbdzW81vC6Q+Sqr5TbWyS3dmFJNmqp3lp0Kd/ZG2kVHKhsjY8TZReMkZFMezmEKzuSELFFZiAWYdSPzq1KsDIsEDy+TgENgDLc5PP4UyzhuLthbwq0j7SpA+baPYdqZqk7XZVeAqwVoxnGBg5NaFrZFWlje2eQshCb+3ufQVMlm22AeXGNnBcNjcfQ1opGq3AZlilEmMxxPyAOoqiJS0sYksccdiJJn23SuERV7jucelV4IR5yx3UkkCMGLHYSQuM5/HpW5qVtJNM0MUSoADtDycgE9PSq2pWX2S8ZLos8xiy5JyenGTSKg01buZs5a3gWRGFu64dFUbScdOalkjUqskrxKjfvCsbZPPOM+1WbGUG5Iht4rnMZTc5ORkdR64psakpIIY0C7SSGGM49KLicOg1bRZrWGQS+eTuHJBKkc9PxqtNYxwM0szIrSD5dvrU9zfW0E7MkRVhGAO+RjknHpS6NIk8k15PaeegTbEXOFVs8EincSpyiuboV0byZN0wjnaRdu0HG09mqLUJpZ7kl0RcKBsi+b9f1rVuLdjavKzxxjHAK8t64qIwo1pALOF4pgp8x3Axj2/CkzSCj8Rkw3EEMEjurvMQFjGceW2RyfXjNPd5LpS9y8jyxqqqAo27fQmmG086VguVUjDcckj1qTDwIqXCyKOisvOOe/rSN/Zx6bilVC4wR3yOlRFgHAKggHPpU0rxIoiWQEk5YkEY5xj3Heq8g2swPODj0NFyoQTEbIPXKk84+tAC5+UYAPBJ5xUscUpVCqsTJ0GOadLbSRITIhDKcHJB5+lBaSGRN5bq2Nyg52seCO9EjF3ZlRUQsWRV/h79aP3kR2yb89ApHGPaliBkYoqZI5U45H1FA+RbjjydxTt8wP8AOlRg7Dpx6+lKHlt96j5WYFGBXpUltEGmiIwjMCQM5zTJaSWpbs7ZI5tzN845HoRU15AMRmVxtkYsRnkfWryou5FuikcDjBZRux+FU3tjliMFFO4FupoOXmvK7MWYxCYmEFk6fNS7dy7AWPHyjHFTXUJjDjnAOVXb1qvGdjhmbco5wKR1pXWg63YwsDIGR05AUc0tw0hlV5VYM3Ug9f8ACrl1IjMn2Zw8gGMqOCPSoLtlmfBKRBY+GYHMh/pQEd7tFZSu9uzDs/OarSWymRvmKR9So7Gr80ToyQzsq4XcrL1JPrUJbIDSEEnjOehFKxpfsUmsfMTKPlR3qk6PYzAyZKt3rTd3GCMFT6U26VJEMciHDcrSsKVyrLcSPEwQHcRjjvUVtIXdi4Ib0PFXo/kADAHHpUc+1mGThuxqXc5+XyOb8XXktpp7yPGU/u4PWuQ8KwzXl697KWZ855r0q62yxGKZN0ZGG3YxiqOjaRDZhorcALksPoe1J2SOaqne5fsVypPbHQVa2kuNrfLUkEXkDnp3pwJB3Y/d5waxbI5DN24ckHNW7bacFiM0kyDaQi1XhKqxD5zTRki7JMqZCgHiuX123+0RSFvTj2rddMqSTVdrcSjvTQNWMbwvZ+RaHdyd1bs6OqZi4U+tQ2YEUbqvY0txcAIdx+ldF9C6dNvUy7l7hWUqnAOSfWlthfXMaq4CxFsgn0q9Ahkbcw+Uc4rQlOIl6CobOl6aE+mweWhWMIGxgswz+NTT2p+zq4UFl6s3eoLaUhVDYC9TitcKsoHmDcv92miXeLuc9Lp0rHESsy45fHTPbirUOlSM0Yf77cbX4wPWt21XynJU+2xRgCo5Fk3FtwMnqe1UkkS6rk7EysiKiRkscBTnt7UJKVuVUEtJzkYyKgmO2NJGcFpDkvTVd4t5RlJHzM7fyo3FCnoTCSZA32aYnAw47++KiudrsrQPGd331PHPp9aLq5guI4zHEYXRNhZeTIx7moVWSMFxAWiBBORxxTOiEer0L9lIsMsnmbCG/dsZOdg9QexqC1vLieaZ45VDRp5YcjAKjgfjUriW8n8/EKMQBgcLjpjHrVu20wWqOZCZFVgTjv7U0KXIld7lyGDe9pZlRFuAfdO3Jb29qka+it71S0guFJ2K0a7csBxz27VNMEW9intLZ3iJ27rrIyuOlZSxG6PzwEiKTc55KkUHNFRlq9h1xcNEDCs0ckpAV45c5yTzg98etWIbUanbTNboI0dwJMtux0HX3NV7+0tVvo2s3+0BMqcx4CknjJ/KqMEstqsu1j5sLbjuPyFc88UjZQUo3hua9/bmK8gs/sUq3KrhvL4DKOhX365qnJ9qW2tbmBomnjLKkLgblHTJB7+hqWG/hW5ilu5L24LKdjwuQUyOi+n+FR3KL9ntvJu5JI2PmMAPniI4574oIinGykYbm6uJDYhQJWfe7HnBPHH+FSwC+tZR5mZYmGQqHHT2rYh03BMjXNuvlSFZA7gSNnnd+VRmzaeaWezLShJisUob7x6nFFjodWL06E0km+NROnmEgsmeifhRbwb7Lz5JlGW2Iu7kfhSwWs1vE895ACpfaJA4Ick5wRTd0jTM0lv5Tlt44+XHbFMwdrWiNWKNQ42khGAO7jNTAo7GLyfmAwC3APvV/wAw6kzLbxySXM+BKrqOCPT8qzriJFt/Ne7Mc0b+Wkan5zx1x6UhRlzPXcxZdPZYnkaI7wwwd3BPtUBaOS4hjYxpyNxZsseTkmulEVy1i0UsaeUU8xWHX6ViHRIppItk5JIDFWGDzQddOqnfnZs387zSWtnG8f2a3B2yKvPPbPeptT0qOxn/ANIuPMSaPzEKncR6A/Wlgt/MZYQoTn5DkKBgZJpksFuZ5LeO5S4KANujOd2R0HuKRyXSdo/kZ4tMpIfNCqBkZPNPt9IF9FJLFOBPEhYJ0J+lXrm9tXESNbRwICASgyxwOv1rLuTei/U2sxtpmBU7VyNnbPvQbQlOWl7FJ4/uGYhCVyp3csff0qey82SZhb+VIzjLNjBA71SaU2ks0SqRcuwG/G4bSPmBzWvYac8MlsYnKmXO/nBI/pRc6KjUVdltZ47TyvtUZly24mM8lcccetVhLK8cuNvy/PtbjHoKki8mGe5aJg4ULtBGcn0o1WX7ffrcWlu0TFQDhMBRjnHrTOZK0rW+ZWeJJ4POmcx5HygHgVmzIm1fKyCevete+t4mQGC6WeBMKpI2MD1OR+magndCiBIPlLfNjjn2oNqcuqK1lA2SSrLgZPHP4VNICUDE73BJWED7o9a04biIIl3dmOYBmjWFm+bHTJxWfdxXPyEkW7yruGeSV7fhQJTcpakU0dvEjbJfMhbG5guCD7A9qozZVWOzcMdcduxqe2mRrxPtURdYwd43hQxx2NRgq0uSjbGB2c4ApGyunqUFfdnacxnp7fWhi/3ZecdwajQFJi5UAhsYHQj3qReAGVQTjr7Urmk1YY7MQ2QARVQFggJO49yauggAMF38bWHeqN822MtjaVFJkXtoQTT7AQ3TOM0uiTySXzrHghBnmqUsm+NSuMZzz3q14JHn6xcqpHoSeM1DOeu0os6WSZFgZHTMhOQccVTwzNiMjHXHatq6hE0ZVUA2dT6VmNEq5UZ3noRWEjmi00VuQ/qO1NdVLAkYNCNyM84p/mA9RzVnMhBbk9+Ce9WJIUgs2kbHSml923B4FVtQlynl5IU8YojuW22jLWXapAB5qAo7cMepx0rSS0Xly42gflUIdPNCxklgc57Vu0dFOokrItJHsiGFPH61E+WIYnOeCKmnleZdgO33FNEW2IbfzosVB66jt6ogBzkkE+wrSsbjdEC2c56YrJIJ+UJ17mtmzQxIqdTjJ/wpFztYnmnKcgcdAB1NRi6yDuB3E8gc1YjiM0nU7yOQO1Mmt0CYQ4kGRz6VRmuXZlPzeuRkenXbSyH5QzEMQOeeTTMbXMe3nHUdR/8AXqxZQSMyn5VAG4ginexrohIVE7YCbSATkd62B9u+y28HyfZ7gg/7231qqqrHlEzluCF5z6mrFrAk10IVLROxCqzNjae5NFxSknq9i4trLdbUhjDyE58tRgYB61YidkVUwQztkqwyMVHBG4v1gaRp1I8pSGxt57Gp54/IuW+ySmePKxqxBHPoKq5zN30uWLqWV4Ire4uJFtv4dsQyjDpnvioNMuEmvvstxPIiTMfMljA2MPcemcUzUYLm5i+z+a0Ig+f5lwxLHHX0qK+tnscRlo2uoo2HlOo2bT/EGB5bJoISXLbv/Vy3dpd6bp16LBIGtpGKyuvz4A7jnj1rEge2uy6SpIgwZVDc+YQP88VZjia3E1hP5i6jGyEBuEwerH8D0q8sDxWENkIIZI2lLRXJmAIydufoD3pXNYSUFbr3207+ZnSfZrWaGRmkktEbzMQEDZkYPXuD2qO43tDDdebCtwCYmhHJK9Qx9sVoyWGnrIlnextHJFte4m835WXgEj356e1QadBaHV5ER5ZLSPMZaNdxfn5eO9FylNNXV9PxHCwtZLMuJrJrkQmXrhQPQf7Q9Kxv7SuLC73SskKSLtmEQ++v07dByK2ddaxl1+Ca1heOBm2tGFAPGByO341FqunrHqUUVlE11uUYiZMMq56Eev8ASgulJWSnrdX1KSJbXARoUdiwwELYCuen1ArSkv7prWSzuGtLK3RfLeRUz5rgfo30oj0uKFdtyTZzPuYxOhCoOcYPfpWRLar5jKoW8DZzuc7SxHBA9RQJclR+n9eheiv57QwxXM01vMQDGxXa5XsfpzVK2vI21SRmBWVF2hu+fWqElr5yt9uMhmjG1GLklAOgGaZDYyNGsuP3u7q7Yz6UtTpVKCTd9TrIMXEUSRyOXPG4ZUqfT0qmHt2D28iu84YFJVOCPWpLLcqEkh41ALgDO72p80ttGyxOeCvmRmFcFCT90k9aZyJWdkT+ILgSwsbe1dIERVRW6nHU1QhkFxbxpHbFGiYMHAwee1asRlvIULjzCqneoX5yp75qtfmTzN8bcqoRfL4wKRMJKKULEFtAbkkSBE5ZjuODx6Us85iBgMbznOf3a849zSCIlUyreYDu69a09QaK0gRoZMz4Aby1yGBHXP6UDcrSS3MbFlqERCQSRvH98sMECokt2h1ELZyM2+PDCVs49637dNPu7B0cbZ3KfvGbaAehFVNVtUsCyQTeYU+USZ6gUtyoVve5NShK8lkY1t40eSPoQuQc1DBd+TO5lafIBACqCAT1pCs6qJopNzyceuBVtLG5ntpAZREFUyMxON3+7TRs+VL3gBtLy2dLdcScBQT+eayrje0oaQqq5xheiGr1pPJaworCK4tQzMPMTDAkYzkc8dcVRdTFDtIkmB/iJ4PuKZVNWbRqWxtFmiklYhcZkAXdufHHFVNXjjdI7iKfMj8sg6qM9D6U+3uiYIYQYZCH3PJIg3rkgde9RavfrFJMLTE0Dv8AMGX5jj6UEwjLn0KbRhCN8bAn5oiehqtI5K7WbGSSAo6H0qbeHRHfzPJbOOQQp9qhmUDYACpbkk9/QikdXXUrKF5GAGPXPQiqtzdG3RVDbwn3QT90E9KsyPu6qQ3qexqCW3EpR5OBjBHYmpa7D63ZDHdeYilc7/Wo7qNrghWUgHlqtLBBGP3bEE8D2pZG3LhsH6cGkZSb+yZrWiRRhV6irvhiwWB55VyGZsiq9zlo8A8D061t+HZQ+n7SOVYgmkzjqXRot5ogbOQTwaohiudzfjV+eU7AFORVBw7sCoGK55ErYzlBL5WpCpPJ61FGduf1qcnI4rQ40yPnI56VRvnLSopPU1df5Rk96xb+XdcIo4IOaqOjKvqWmnOCmOKlQAjkfgKz5XZXDEHYPWrtuS6hh1NbHQkkW4o9y88USXAjGzazAHqFzT42VEGT14qcEZ2gYUe1MtblS1u41kwwJPZe9KuoKL1xcAhGIICH7oH/ANenEFJvMUAN24qpPAXBPfOS+Kzd0dMFF7m5pN7bpEHkkbzZGyPUitCVSH+ZcZ5OOa5FWki5zkqMAGushtZW0yE7iWZMgZ/HmmncyrQUHdPcrySG3nWQ4Yjnae9WY5IYrduczPyPx9KgXafmZBtHygk96ssGtPJYtDhoiVO7P5+hpoTtaxNBby28n71wuf4iOABT57+N5lFu5luJuCx7mufutUuFfCOZITgMvX8BWxba3bXvl26IbdVYfNtHb070XRo6E0uaSuba2862MsMrxb0dSTu5b1AqfVrG3sI7SWVpI1ChhFICCzd/w96y9IlkSVpmlD4YiPeM7u4+X3xV66MmpXs9xOUeVUZ9jNgKfQUzlcZc+r06lSa/Es7q0TNIBtijZyQB659B6VWvpZ7pYHlDgKSqRkBiATzg+3vV3TxcXOmTwLuiiEjTGSVc7sDlBxnP401nMxs7eIbIyuHkxg4PBGfT3qjSNouyWqIo40gubXU7ZSFZyiBptzO4HX161PZ3FxAt3PfmMS3Kt8zxBiG5+Qf3See1PtdMVbUwyssKQq08coAyW+o57cVThuNQudRinDrNcA71aVRyqjkn14pWBpTT8vy6EkbaZJcW816t1Da7QjIWDNuH8Q9RmpdPgk1FVhkfzNLtnaQyw4jkIPY5649K1GsrXVZYJZUNtBlgt2yBUbn5QAPqaZr+mKtk/wBit0jgMgjl2ybt7j+JPw60PUx9tGTUdn562/4JXR7K31F/7OMlwroS0skbDygeMnPcetGqzy22sNc6kk5nmjH2Qx/IV9GPPPAqjKWOpJJdxn+zYwI3iilIdlAwc8+vOOlXLpmtNXtpl/0uBoxLaPcrnKYxg/jxS8inFJq+t1/SuVLrVp74uLyV3KMcPIOCP55q7p0dmqCd4ySqZWLJU7j/AEHrUsWjzw2t9JqYhUhMqqjcC7crjFaLRTjTFsws4uHhEzK6DIC9l9frTM6lWFuWG3kc1LYeaE2ENOSSQx2hfTk0WUcEY3XltI4k2hTGcEY6kA8GppJVuZYWaWJU4WRimAn+NXbu506x024jUpczFhFbtuIdVxncF6AU2bOUrKNm2/63M22fbNI1tDL5cfDKRwR2Jq1bRC4aGHTQXu3b59/3QPaqcbSMg3SSFph8y+w6E1esZLnTULErHJIhG8cNg/yoY536b/1uSadczWs9zCbiKDYHVnxncf7oxVfydsZdEdIXOFD98dcVTtwGJZl+b0Pf3rUYyIFivJJA0eWWJh90n29KViJLlfqWooIYrc3cxeNUj+TbzlqbfyxzzJ9qt4rBfs+ThsmQjpjHQn3qsolmjVJJEMKAscngZp0tw80LLsR0CDA2Y5AxkGlYzUXzXbLrDT79pXQNbRRQo0cbL99+9ZttKX1FEmgEltDyU6Kc9s9q2LHRjNpxNzcLC1ygESOcbiOQT7VgyWxEkyG5Ci3++N2Q3POD3oSKpOL5op7DZ7ZrmaSPT1WPJJKA52jNV2it0glY3bLLGQiRjnd6nNWbTbbyvcQs+1so2DyQaiKyysPs8caqMkNJwDTOhNp26FKDbI8aM2584Kk4FSuZrYXNoIzNbkeYuM/Ie5FMBghlD3FuCpcAsrYIPfFRzicTv5JLRODsYmg13fkM03yH1EGabyiOULR71PqCPX0qS7nhubiWKyRFEjNI0jkJ9Vx6e1VGQSRiTzWS6Q4MffPrT7dkkmV7ny2gjkUyqQFkPrj16UGjir8/YqRxlUM0UeFUhXB6ZNNdnO9funaVORnA9q0L2Wa7eWRUZrTfuwo2jHbI9RWfJHJHtkCllJ/ECkap33KbLtVI15wvO7vSD5QMZA/MVsaHFY3OrRLf4W3YMeW25I5xms+WDbcEMrKhOQfbPBoE5pvlZRnBdie/Yg1WIJI7E9GrQl4nMaqdpXO/tVV42ySh61A3Ky1K8j5GGwT3rX8LSDyZlOAC+SCayJY3RSc8dDxVnwoNv2syZwWAHtSkrI4cRZq50VzImdsY4FVlbbnODRMuM7earuDt/nXOzFaopEA0m5kHQVLHjHankAjkVociY3eHj5Fc1rsht2WdeNp5+ldIMDjNYviVFNi+FycU1uO9mX7UQ3lgPutuGc1lS3RtnEBDMRn7o7VL4LTfp2XJ6nFW5YQs7MF74GRW19Dop6SsyO1FxO6uyGOID5QTyTWyqiNSW6+pqC3BKggfiRVgYI9Wpo3dyPCMSSQT9elRx4+bkbe5qyrAHH3vUYptyVmiKSj5f1oZpG5l3O0OwDHpxjkVq6ZqMlzALYqxeP5i+eAP61l3ESRIVQFT6itHSUkjhJgUsDgZzgg56YqVua1EnDU1SQGjYqBGwLZzz+VVtYk/0ePyQUbOccAYrRgsbmK2lnBLyPwFK52+1Y+rAtdjzGRnVcuB0z+NU1oY0WpT06FCJCceUFfrtx1571e0uyN3dgQTLGEw2WH3m9PpVbaTLlFVCAPmB4qzZNPFdq6KPKc7Q68YNSjubbjdHVae0cbtJqUTPNIuFETY8v3961rqGCK7e60+6+zywJtIlAYyMw5wOlZmnWedjJv2ysFV35wRj8xjtV/VtOFlqCy6pKTZXJMnnWhH5YPQVXU8iTTqWvr27/Iy9Kkv57sZ/ewtLsZd+wPx0474zV23BvL2+n8n7OiMGK8nCjsT6Y/nS6laPPpbao0YMPmErLIwQsvTG0dT71a0JUntjJb2kgjZh5kBl4dFHzZFPQKklyua9P61H3WiyjUpPIC7XRZirn5YkxzgnrTbJ2MsltBEkkYO5Lh12siYycgdATx+NXbkpcaRcyWGoN9ljJZIJ1wQvTg9xntUcMKxw27RSzWljcrvlbcHYlRgn+XFBzqUnG0vTr/Vx4tzdEXE6W1paYO0SOVjYjjIX1pkBme2s7S2iju0WQXAJYMyfNyu3jqOxrLks9SuZIobeVp4t2yBJztcqeQw7Y4q1o6zWMM91c3MMdx5bLFFIM73B+bofYUFSglH4r+X9fiT6jHYapqi2tuJFkcYXzIxEirjOBx61yup6hNBc2+jalnybJ22MPvYPbPpXRTWepIhk1K5trSIjOwyBmGR1AHbtXIRyLcX8cl4pmtlbMriPcwU8fnQdOFgrPW6S/HyOh0fV3MNxbNKDHOvlCWY52Y6fTjvV2K4aOzW0sJhPqDkwrcOx2GPHKjPSuGbyop3Nn5si72K+YO3bNXLWS7gkVZTGqDBEbHGQe4oNp4SL96P3G/qFnfR26y/YNlgFAklOCGbGO3bNR29tBKVRzCkYA2ucjbVq5aVrSBtQd7e1kUvCqEsDzj1qO/0y4gukgttjtJEsqhuHwe2O5pmEJ6crdtxugrJPrUISWEDODIxyAB7dx7UzU7xZ9UuZJwoXcQuwYVgDjgdqtPZTR29xcT27LKCI0MabQkncN+Fc/e4gRX2i4dsh3UnGc/56UF04qc+ZehsW7BxuwpJyME44pk9zPKQ5lUBAVaQckZrGhu0lKJKzBM/dXjnvW5YW9nHPOk4na3ZTsA5O7HFFypQ9m7yQ3TlllWGNGBTO0Fj8v1NbulrPa3Ecl6qNaxSFFXcO/UiqOnGD+yvL8t4rsyFwzISDGPT1rRSObU9Pge1itpFtVwx6MTjknmkzkqzu7bIv3MVtfalBFbBoowpfD8E/TPb2rmtQsGXy5PIWNJHJX/bxWjqd5dXtqq2ha48iMM7bArKOnPrWdq99H9ktrZMyiJN3mbdrDPUGkicPGcbJf8ADDJBFFIqyqUdhkqpzk1SmlkebZh1jHUNzjFNaRmQsrh3ByHHOBUW0vG7SMxkb8sUzsjG2rAzIhjRR5iM2ckcA0TKphYoGdB8xKjgc/pQlvEIgZmfYjBmWP8AhGe1DQG4vAulkssrbPL37Q49DQXoR3lsIdMguGkjY3GdtuOXTB6k9qt+H7a3uLiGK4BijUtIDOmUdwPu5FQT6dd2N1HPqFhKlpG2wqr4DewNdHo7m4t/st3HLHpqhpkmjy3kMR0Lf096VyKtVqno7+a/rVo5e+uGtbZyoZlDBjGOQfwrCuNeh+3MsIl2BOgXqa6zUryK+kaWCGPyFxGQkeF4/qaw7u0jba4EZCDCELhj9al3OqhKKXvx1MOa5aW6LpFKsXUZGOa17O2ubnT3ulkh8pcghpAGyOcAdTVqG2JtDciEmFTtZ8cbvT605Ih5DTKi7N20cd6aVh1Kt1aJgSSyq2GTdz6UKQ4Ixtb3rWuHVccL8wyMcmqEjrICVxn6UDk3JbFO4yqHdn2NJoc3lxur8kmnXRZ4TtAJqppQwzN74qJnDiNI69zdEu44B5pwjAUd8ioYyC2EwSe9WlUIuXIzWDRjEyYyT1NTA5WqkZzzU8b9q0OZO40gh89qivwrW7BgCMd6mZtpzzUVyBLCw9qSHJGBolw8VzIkZAjQ5APetqKbzp5FwQR19q5i3gki1GXadwB4HvWwwliCGFfMkOA5JrTod9KKdmjeG2PyxuIDdKmUHzj0welZKzXAUJsIx3PNTp9pjAkcDGeDmnzG6gaJBLY6cVCByc9AM571UutS8oYQZkPTJ4FMk1Cfy1CxLuYDcc5GKOZGqpS6EWouqkruIz8xHetbSNRCrDEVVVRR8xGST1rCZHmaWecKm1gAD71NZXDQJKgXczfxHggUJmlSmpxtu0d1Z37RW7ToSZm5ZX4C/SuOabzp5JGYOSxPXP4fStG1db0xswbyz/FIMcD271Ua1aKU71TdKN2F6IM1bdzmowjTb7iWxZmYsOTk47CtOxkZUMaKjndgMetUECiXCAhT+VXoE3zxhCqgZwfWpsbys0b1pdT20qOm77Uh+Ug8Ci7zeQ3LZX7RK+8hifkHfb7VWt5DLJyN0aZXAOOavW10kr+XjaWUpuHcU0jja5XzJajdJvI0klXUBLexwqGRXbKp6kjuK6fS3hmt2msZrR4p5stFnEiLnARR1JNc1JYw+RPGpHnZ4+UkgDrVvRtRtjaT2+o2kMQA3wSquG8z374NMxrwU4uUf6+RtSWUenXEk8AZWRtrI2N7IRluD0HviszXY7WeO1FnbmKBNwEztkjvn3NMjaN5GgO3yzFvWY8OT0IJ9KSEw6pHbWOm2v78qVkLN1I7+1MyjGUWpSe3X/MsaHYLFavf3nnpK8Z8hjLlsg8kDsCPWmLpbXuqwmO3vXsmDIH43bPX8zUcFpaz6fOttDd/a4mjh2vICFcnB/A1f0m6u5Naitb3yLea13J5kuSzDHTrz9aBSlNOU4vX+tjIvJJLLUbiKGUBZXEULXGG2D7pBPpW/NbWFhpUN1dyNcNHIJJ3j4ick4YY4yP8KwPE0nmwwT27M84BjmEmNoAbgLWNr93eS2tkbpGDRrjzC+Q3tjoBSaubRoSrKGtu/cv+LNIsRfST6VvaIlSRkYUtyMe1ZV0yN9mjeGGCSIFJCoJbg9Tz1qMajA9n5YtY3nfOZGByp9sd6aJYPM3rAxiIAILY+bHWmdtOE4pKd3Y3bWORtMEuGnV5fLiVSCSO/HUGn3xvPPRyl2ZlUOjsCGVRwOfQUxZ5LS6haxt0W4UqyzDKBwB0UH1qe7l1K5ngm1FxbWd5gSEP95d3OR1FM5Xfmu7W/Et6D4olsoX+1KlxbSSEnzjiTPqT6VB4xFpLp9gIC1m0kkkrRknamehx7jpU/jbSdJtraNtPV1ZsYfzPkx16d+K5G8ne5cSTs8jogRWJzkD19qW4YelCpJVoXRUWJWKmctHGSQZACQT/AI1oWlzNFF5rQnYcqpY8BscYPrVuGG2h0+dbhp5bWSPcpiTPlzdgT2rGTMsiQKWjjd1IyTtX3oO9SVS9+h0VlrGo6HdwtcDE6KUaOTBG0jOK1tPCz2LajbzE7mxdxIoXYP8AZ9eK5mfT5LfUYzPOZoHkCmVRuJFdnqqqLZEtIJZLW3jZDcBcKw6gEDpzxmg4MQoLl5d3uzLvbqaOwK2LsLUOREzgKZF6kE1g3l40sRcEeYp5HrU41RIoLcRgkpvDJINyZPpWRcIjhWjAWTuq9xQdNGjy6NFqGZ0dyzZAGXXbgY9at2F9AEkinjWUkFVyccev4ViuHMYZuVzjr1p65cbYgW3YyMcjFBtKkmtSw1yy28kCzFSH+Qf7P9a7aysIryBNJhuUaSP9+jJF8iMVzhm6g5rz0j95hhtx2J6V0U2jX9tpNtfSyCG3c7o1Z+TnoeKRz4mnFpLms+nqJ4imvbWZbO/uEucEyFhIW+bpz71UN6RbeRbTy26A+Yy7j+8J746U7VrWSxlSGWS2ka5UM7owbaDz1rOKqjuHkKgNhSw+bGOPwpmtKMXBEkly5DrBK6RsdzKfuk+ppkLyS/K/3k5z2quWbf1C5/nUbPMMrGAMjGKTdjfkRsWGpLbgxyRpNDJglSSVB/vAevap7S7ZVu0hCCORCxDjOMdx6GuTmguETCtgDoB0Aojk863aObcGTnK/40uYylh4PVF6f5iSPrmqbZ5YDnvVC8urhT+5j+RRjnvSwyzmHcMHNSza1upcYFY+B8veq2n4ww/2iaeZCIf3hG4jnFQ6aQztzxnNTLY8zFm7BE+xWVThjhTjqfSrNyRGdmxlYAAhuuafEIrm3hUySRtGu3GwsOucjHemXxaScEb9qqFBYYJwOprI5oM52NiVwDirMfUVQibkDNXF6DB6VdjkjImfJHFQtnYc1NHkjHb6U2RSqn19KC2zIs0C30x9ccVoOuQDjoay1WQ38rxjoOtbVhC7xLg7mY9ewrRO56OHiuRSZPbsx6L90d+lQX138wVQMdx2q48qW6Kj4bHYetZk6JLKXA2g9s0HdRgr3aAQrMBuCsO3FTrGEQiNeOlPjGUVUAVR3FE8hijWQjPOABQO93YYYAQdw5JzzWdfxbMng9Mk+noK3rqIRCE7x+9jEh2tnHsfQ1nvD9puVQ8rkZxzihhTn16G5p8HkRxSXCxySkAooH3afqJjjjZggDvySBUiokMKrnLKvfrms65ldpFDfMwGAo7VV+hzU1zS5ipO4RQ4GQnUDvVmCYMplA2hVJHsfemRyxi6WOYL8oJ+pp9wYZpt0S7ePmI6MaDpv0sbHh/yZbcJdKyiQ7vkbl/x7VrmORbYhjHGwYAKg681xMiMrRyxv5SklsRkkj6itbStSkvFCzsqovD/ADfM/wBDTTMa1Bv309DtbWOxgtfNuz9ouHJULG+11x/F/Ss3w7HcTa4bm2WJ7qJCxW4OVx04A71lmUlI50Kpg465LfWr0W5rlbuyRBcxHzFjGccegpPQ5HTcYy13/qxMuLiOa6vbtYb170RtgYUL3IreuW0SGOdrS+lW6iXyvtKjCnj7vy9Sa5y40u2WB5Lu+QX8zCdGXLIynkgEdGzW1qWt2NhFZrptjDKzKdjMoK7s4LY6/nT3Maq52lC7/Bf8NucvfXItLjz7B38vduRzwd3B5qbUJJjqKu01vNPcFZ2mjbO3PVQP6VVuIZLy8unlWOGTduSNScMxP3Uxxn2rs7nw42o6dbSJpiW92AN5iYKMDjGPX3NM6alWnSceb06DdeSWJ4pof7Pmm2gpOAP3hII+YdK5fULWWTTEMtwjylsiOIbj0zj2qxfo8ty1rbhFeMkNBGc4IHJHr0rodNs9Os7C9vNOmtpybYGRnJ+QnqAOwo2MFL6vBPd+n9WPMI/MguFKgqfp3rUtWgEjS3MbPCT0Y9T3q++jHV7XV9TSRIUtdrqicqSf4Qa5+NJInDRyDCjJ3Utj1FKNW66rc6B9QjjjR5IEaIuWRGkZsDsPbHWo5NSMtlDAscAKE4bowJ5zmsF7iZfvKVBP3tuAals4pp58DLEdgvb39qdxewjFXZeW7uGgZSBKFbeSSSAp7fTNUmYDPYd8+voKt3MDqJpBJAUDEYTIB+ntVeUq0CRLb4kDfNICTkdhQVCy2F+1ypbNbBnRGOXUH5SR0P1q3YQp5e+S7jQlfuFcn8KzgjZEa8noVb+dWI2ltY9uUZZFwe/FBU43VkdH4WhS4uZpbm+RBCCVWRNyucYwB610gmvtL8NXEV75Tbj5MY34lZTzx+dYfhKKwlswqzBb8t80MwJjdR/WrXxAENkILcAvJ94SF/uA9lHb8aR5FX97iPZv8uxxV2jxP5ckbK6DBDHoafpVpJqVzFYwhfPlk+VsEHp6+lQXAkckbvNLDPPJNbnhOdtNWKRdPzeNciNLl5NqgEcofrQepVk407x1ZXv7FtLL26vHd3HWQxHIjx2JrPHlJbmUyFZC2PLAx8vrmt7U2mJube5/cBpCfKQAgsP9r0rF1WxltJI45y0fyj5SclPrTIoz5klJ6v8AErC7aD5oVQkLhmI3ZB+vSo49Xug0X74ssedgb5guRg8HitSABLVbezjmluJMmRDHgMg6H39aZq62J1MxafEPLVFz5eSCcc4zz1pGinFuziZLXzNtyoyoAwowCPen/wBpNNKiXBDIvygkcqD/ADxVho4Ldw0gJDA/J/Ep9x2qncpFcKTGACKVmbLlfQnu444ZnSNxJD1V8YJ/wqCN2LMcjbjj1H1qpvljUJIcqDwaniUysgRcsx2gD+I9qAsktWP8/GRnjtUa+W4Y427uCPWnTIYmaNlKyIxDL6GoHX5c45NJsnlTWgk4ULheMCnW5htrIO+HkbnBPAFVSrADJyvrVGWRfsrCcDABGcc0JmNWNluRX2qQqGAOG5/Cr2gDMXmMM5ORXmt9cSSX8ce44YBjnvnpXqPhZzDBCQAxAH3hkflUTPLxFTmemx18JdrSDybtIcLgrvxznrVa6WQOfMlErYHzA5qdb5uP3cBP/XMVVup3mcllVeMYUYFZXM4JnHRsMjmrUbnjBrMtzlfer0R28VqcaZoI3Ge9LKcrVeFiT6CpJThTj0qSyvpjr9unVzlSBgVvW80NvGXXB9BXLWzj7ZMB944rUAXy2ANaRPUoxTgri3cqSOc+vaodqkZZ+D0GapTMzSCOPv1yM/jSi1bcQoJT370WZ2qajpc0lZTIrgngbcZ4NSCSSeQrHjaOpI4FVobB9n7yTC+hNXtvl2qpGdoPYdaCOa7GEoQ25xwO5qWyUlhcwMm1RjJPBPeqy2CysDK7MueFJ4H1q4VCKI1I2r1C9BQU9dEXTKrQqd3JPJzWfqUypgqxwO47VIAAB/CqjjI60xVjAYsuBgkcZK07CjFIijjj37nU72UH6VPEcE9VB7HvTThznadw6ZPSlc7HHcgdjVItXZY2QtG5uN5JXCBTjB7Fvasy+do5TLE2+4V9rOq/u9o9BV9S2TyvP3gamguGhfEARGPAJHA/+tQ1c0i3HXcuJO01q5mdQWUZIXkCtbR7mS1vrf7JNHbvIChZjwB3zXH2NxJBeZI89pDgMeFAzzXQ3AQ3MczRqxx8xjPH40t9TnrUre73O90vR7iNLaK6hcAyM6So2FiXrxjuT60nxB0q1/spLi2VElg+QIuFLbu+azNI8R3lrbubmY3ayAxrCJMPHgfe+lQ69eSalawSy3KmG4iLmAnbtdOMn60k9Tx406yrKUnocxJcXEdmbKCQLbJL5gDkBlfGDit+DWRd6OkH2vy7iRjC0SN5aquOHJ7nOawNPig+9dozQoC7AMEL9htJ6nJ6VGbGZNmEYGX/AFSgZLA9qs9apSp1NH01Or8Mw2V1dTW97aTT6qU3KYmCoyYGCD6nuaoa5rduz3cWnWa2ACiJ8/efB5BxxWJtaGcSGO4CoQgkVjkH0zVlJ3KXMhsfNuEdZjMTuCKOMMOmPrQZfV0p87d1p12f5Fya4ubPwpBYm1MKXshufPLD94o7YqvZxWkens0vmQ3RG6KbJ2tjquO9R3yWsmmafcm9aa4d3E1vniIZyNo7CoPtCl2iystrGC0YkPQn+ZoLhC8dO7bGTvDcxLDBDKsqcDL5Dtn7xB6cUmmTiMuY5mVl4bHGB3FVvNlijkkgfAHBzgkk1K1/EdIa3jXy5RgkheuPeg6HDSyRs6vcWd7othFYRRo8e4yuQA0hPbiucAA4O9V6HnkUWQSaSNEDRZGWJPU+1XILaMysryszF8DHOaL9QhBUU4lEYGzy2ZnGck1fju3jspoXjt381VIbqy4Panz/AGSW3EayASIxHPBFSS2EtvApkKxyIoeEAZMgNK45TUkkzR8BQtd69BGBmOM+ZjeVxjvV/wCIFrHb3srPYzJJM28XLSbwQOvFbei6dPpsMWqWQF+9zGkbnhNgzgjH9a0fFWl23/CPTK8rxjbwFy+X6jnk0rnjTxaeKU+mx5nYWciWUuoPMsSMfLRVGGb/AOtVjRrX7bBJJGk0txA4Z13ARoufvE+tUvs1x/ZjTLdpJaQSeX5e/wCYE+g9KqLLJbqUUtErcFDnBHv61R60oOafK9b/ANI7a/S41e1WWW3szNfTrBC4OGyuc4PQZrmvEdpdabctbX8rGYsCpbnd+PcVZtNXlgsbdrcAGPco3gFFbuR71k3Ms11Mrz3nmIB8rPltvtQZYelOnKztyjILu9juYp4ZZDPCPlbH3fYe1Qz3Tz3huJZWaTdkmMbc+4p6uVIEUhEg5yTgEVAxxIZEBjkDcKKR2pRvexJctPNtmmDljkrKV5k57nvVV0dDvK7GxnB7j1re1yVNPshb6fqDXdvJDjbIuPKY8kD8a52HdJboJJN0oHbn8KTYUpOUOboOjmyTHIvB7VYudQdmiWSOMJEqqoVMAgdM4/nVHO2U/KQQO9OimJ3hz3pDlBN3LF7OtzcvMIkgLnd5cY+UfSopIxJGQ3y54JFOChTg9M/hScrkAkg0MSVlZELfKSD19DWfeQYO7OAeGXsRWlMAwHJrO1JysBJPIHNIymmeaxwvJrky4+7IR9MGvVNCjPkqDxgVyei6aW1Ke4ZchnJFd9YQqigY5xWc3dniu17Ghb20sigopJbheOtPuQIzsMJjdeuTnNW4pD9iJVJdyx+XkD5QCeT9ap6nIGk2hWXYAnzdeB3qBpu557bMAoHGMVoRPkACsi1ZWUeuKvxOQevA6Vszz0XVk29amZsr25qrjcpNSRnanPapNEymsscV+BO+0OMZ6Crk0pERKkbB6Vznib5o2wcYqno+r+bpLwySDzYvU8kVcdj0MLU0szs7Sc3biRgBtARdoxnHrWrHGo5PWsbQW22UZJySMityNSQT1PrVo6JWuNZhxgfMOtQktJKFiwSeDx0qWU7cgDJPHFMhIViCMFh0qZHRTVlctiBG+Uktz27mni0k8zEWG/2SOKz7SUwS4aVV2/Mqk9c1tmcJ/GBnqAalMclKD0KcyMiZkHJ6k9vpUAbcuOFY9TnOAPWtqSMTwHKjJ6HP3axpsBii4VVJzx1qkwg+bchYlnHOcnjHrUsewEiQAnGRgdKjJ4LMMY4Ap0Zwi5wB149ao1aHkgnIUAEdBTreVopQ6EqVOQTUYBZsrn+lSLBnqyrjux4zQXpsVWVp7xRCB5shwDnAH1rdhtJokmiZ45BCQztG2MZ6ADvWVe2rRrbsVljzhwmMkg/xA+mafY3kkUcvnyf605G4ehpJCqJzinEvtKYnRZ49jMMbdpGPcmun0bU7IKkWrQpOgjKQHshJ7/41xlzrj3C5kUSrjYEPp2FO06/+y3UC3MAuELB1jfjJ7A+1FkjGrhnUh7y/E7uG1txJdSPb2+qRmP8A1mdsaEdQPfFZ+pXrXV2k8NvLAYV/0fa4wkYHQe+c0kVxJHK1pH5Qt7hw7QqMKrH0zVq/sol0+MLKondySq8rt7c9jT2POilGSc9b/wBehzd5es9stursIHfzGRj1Prn1NT6Y9rLeSxxwMqvDhLcyMTLIenI6+uDTr3SpbJ9k0HkuTwz8jB9Ky7YNFcKsZCSM6oswP3eetF7neoxnD3DsLfwdZ3W5JbmSznKgpGwzhgPmBP8Agag0y3sbXw5cDUrYKrttileM8nuyt6cdK6vzU0a2W0ljW3tw4C3Mrb/nI+Zge3tmuV1S68ySS1kvo5dLSRgkj5YM2MjgdPwoW55dOpUrXUm7aP8A4b/Iran4esbfR1vYbmMySKGEIlG5CSPlx3HvWJq1tFZqEs585GHbOCTjJBX696ns4Xv9SgtLeWPfKoDNKpRU45z+XWqmp6fcwwRXEkZWGRiiODkMynBx7Uz0KTcZJTnd9jMt4ZRE0uf3Sng56fhTVnlhaN4RmQHBPqKliTIKAnaAflJxzTY7SQJ5hjLLu2lKmx6EWupoLPbT2Ugkt4g4YyCUHDfSrmlXcEF3ZLfh5Ilw0ijrjriqFpp6zkQSxNE5ITZGcsx+lNRWS9uklBUp8vzDn8aTMpQjJOJ2tz4z815IdOVbO1O7ClR84Pp6Guq0/W7HVUa00ucRKkPLSKBzjHAPU+9eNylN+4uSy/c21uaDPJLeAWVszX3lEQ+WAcnuWzVI4MRltJQvHS39amdqEMUchDSEyo5Doq7eAeKpSKZHyhIUjhnNS3kknns0wZZySr+pNPZEt/LnhuQwxkhh09sUHpRuorW42xiiupoLaaYQb3CF34RB6mp7y3TT5JRbyiZASjEchh6ioNwk8yR2eSPPzKoxTWktvMxb+ZtKnC5zzQLlble+hba2ubzSRdLBILW2+Xz1X5Qc96zmbGHbzCp6nqCa0YdTkt7FoF3pDIeVLZUnvxVCWQGVUiGe/A7d6BQ51dSQwiKRdhBbPRj29qpW4fT71JoQc9MHkfUVbkk2qUB4HPPel066ij1G2lljSWJWBZHGQR34qXYu7SdtSrPK6SZaJyTyc1F9oi+Y7WXPWtu6uLS41dkYt9jMuFYrgqmfT2FVtbgsVv54dOkM1qGwkjDBahihO7Sa6XM1Jw65Uj6GnMrMh2kgHgkUttYLvJJO0dvSteFLaUeVGcuBnrUjnUUdjMGNoJzgDFZupjCNnn0961ym27EIB3N+VYmtMEn8ok7gaGc83dMs6RAqQrjtW/C23OKyNNGIxWtGpAyec1jJniwXc1knikttnnpGwjKbWOBnOc1TvmSWUFG3BVCl8fewOtXY/PNtB9kWNgB83ygkHPfNJfurxy+Z5WFKhSuPvfxAY6ij1GtGeM2E2QPStmFt3SuO0u7yFHtXT2kuQDmuqascPma8bce9OJOOKgjYbRUrEhT3x6VkUmc74hJ8tsmuCldo7xNpxlsfhXfa7ho2rz3UwUlzjODWlM2TtG57Jox22MG3J+UH9K6Szb91n09DXJeFpvO0q1fIwUArpYsRx7VPBOcDrTR6N7k05ChnIxjnFZAF1dzeZGuxOgJPJ+lXnzKGDMfLBy3vSecCUSLqf0FRI6aUrGW1u6XMbynzIlbLYz0rodPEF/cecsQSKPgAfxGq91bF2ijjVvLI5I561uWaRQQbggQoMYA71KNqtW8fMc7hIWHyhiOBjGKx3kLSE4GF4PNS3M7zSsRwgBGSKquyJs6bs9ByarcKUOVai7VkJLHB64P8qd8u/CEMFHOOKUbmJLBsZ55GaJVVQRsffnA54Aqi+o0sQRk49s9BTouW+8wPIyB1qD5y5GzOepxUkb8uDwx+7xk0y7aEl1Ix3IhbyQfkLn5gPSoolO0hFPzcMf731zTjHIB++HvtbuO1EbEc7gMdRmga0VkSXEO6LdK0iNkNsVcDaOjZqewsbXyXnuZWLIu5QMElu3/16h85NyGeXIP93qPaoXW5K7o4yU/vetAe9Jct7Gv/AGyzXRa7Rd4AwMEFcV0vhTUPOvbi4hiU+YnllJFyoz/WuJs0H2pJLoFg5yWIrs9Cmht3SXadqyhXQ/KjDtk+vehHFjKcFBqK1HXdy+piU3GI9s21xGOFA4OBWDe29tI8xs3LRxnO5jgkfStvxBIbaSVGngZGyVaH7rZ9Peucubt5drhFyg2h4+4x3FAsNB8qlDRGo+oS6jpdrp7yG3K73Z1UsJienA78YzWVYW8c2oR2d1dC2t1Yl5dhO01NoWpXOm3f2q02GVQVj8xc4zT76VLiYXJVkmY5l3dGbP3qaLUXBuEdE/zINScWuqSizuzdwrjbNjbn8KL29mv44XliWNI1CgRg4J7tj1NIscTTKHckscE4+Ump7m6a1jlssIyg7CxXpz94e9FiuW/LpdozVVA655DcgHqKnlYr8xZpN3OwcAH8KpSZBbLnAOc461oafPBE6F4xKgOWDHGRU3N5Rsu5IySy3UIjt/s3zCQyhiXA9M10Gr6Vp9jptpcyRXIubhixV33B09fY9K583qGSV0Yxgk7UHOBU1xd3d8baGOO7uLpT8gGT8vUYpM5p05txadktyjq7sJ41+z+QYl242FSR6nNO0ea8a5ia2lEc0SkoFyGb2GOuak8TXuo3+os2pIUuokEbI67TgdOKd4SuoLDUBd3MckhjH7tkOCre1O5vr7C9ru224uotNfMyzxGKZTl9w2kfhWf/AGWrOJDISmeOeM10Ouaql5ZG9fAu5G/eEHqAeOPpWHrd/DI0UkbEKOgAwDS31FQlNpJKxrK1tDbTPKwWZgAqqvD5659MVgzYVmGQWJypXjHtTbS4EN0JZoRNtk3tA4O1lx60/McsrlECKxJC+ntVI0jB027lbccncw+hpJdzQgOx45U/0q08i/ZfL8tChbO4Lzn60yKMZHABx3oZblczp3eN1DhSgwAV/lU+mXz2F9HdRojSRHIEi7l/Kp5I45UeN+Ce/vVEwFW2q2/3xipYlaS5WaOsarJrV41zJbQQMSFVYVwDTdS026sr94LqPy5AFYrn1Ge1Z0eUmKHgZHGa2BKqyr5ku0NwzuC2Klia9naMFp2IUIjVzIfmx+dYsd79hupdrfMORnuPSi9ufMuG3TfJk8+orGvAZriNwc44pGigkm59Tp4NWE1wrRqGd+AfSub8Q3Jk1oR7lOTzinXMkenw7gSpK9M1zmjTPfao8zk9cD6UNaHl4qainy9dD0PS+EHuK14ycYrO02NREM1ooQF4FZSPOga9ukawp/o6yM0RcMc8kHp+VVNRiQTAqgQFFYKO3FTwBI4IHKTSMQWyr4Cn0qG5O6Yttdc/3zk/nSYLc+ZtJv8AOMnjpXZabdblX0ryzTrko+CTjNd3pFwCijd2r0qsDii7o7i3k3LVlWyCBWRYyqVXkVoxtnnnFcjBFPVIAy5xmuH1yzKljg4r0SeMupBrnNXtNynIFVF2ZpF30LngG6D6fHCTyrYxXdCQFcEY5ryjwvc/YNW8tjgOeK9HhlfGXbcO1NuzPTpWlFal6R/lCjv1AqqWNtKJWBaMjGPQ1PpxBuk3gYPrS6zLHGrRsgKEdB/OpaudMZcr5S/Y6hHK2IcnABx2rUS5jeEkYBY449a8x0/UJba7V4uVDEYPpWzZ6k7vmQFUbkKpwFz3z3qDaWHvqtjfv4JWc+S/HUijTbdRh5OcDB3etTWElt9nfy5C5z/F1NSXE2I5dijHXHpT2Epv4SwIIG/dgA59KZNaABhAx5HzFh+eKz4r1mu4ovKYE9dvcVsRMu798pVSeCDz9KpA+am9zMKtCigjAPHHUU4iEFApKE8sxFTX6GItuUsp4Bz0zVVSvz73ClRwDzVJm0feVyOREL5EjFR0z3pBFEQDkLkHcDUiF3EjBkIAz/8AWFIwxkuhQsAVHWmXqhsAEbZVcEjb061rWOsS2rFYY4yzIYyHGQMjGazWx8u0BAeOTn60nypIyoSGY49ePWmKUVPSSuaERm/1q3AubjIQRhckHoDmrEl3cxgwTRCOYNl2c/xehqW2uzpt95lq5uYZUCzu8I/FRnpx3roNShtbvwuh01raWO2/elZPknRif4v7xxxSOWpV5ZJSWj6/1sczMTcJB5LrLJPyYkXlHzjb+PtVHyJFvPJljeNgxVgRjB9DVvRrBtU1EILgWcO8b5n4Cen48VoK7W1zeQvcpKIclZGXJmweCD2z1oNHPkbgixp+nK6yGQHZGc4HLHHU49K1JYbMQRQzQPa5LI1zIN0b5GeMdxXPafrn2WOS4vFUpJKUR3/hOOtWr++tbq0tWjurqeVSxck4VHPoKPQ5KlKo563t3RV1XbZ3DWcE4ktlGY5QnXOM9apJYTkCWVCASOT/AB5rSttQiZJYru2e4gj+WJ2GNpPqRUl7NFapp/2RpnuGUMTKRtGD/D7Urm0ZzjaFtSgbCOJjuOW7jvUE9kSrMgOzGT9K0bjxDBPBdJf26NP5vmefHgNjpx7VkRXM11LIYA5hjG8BuuKTRpTdVq8lYhSFsHEeVXq3ZfrXr3w9hEGgRSSW6IzAu0obcWx6+nFeVRXyxzZDCRSQxXHB/CtFb+7kgmgS5eGGT5zHH0J7DFCZjjqM8RBQvZB4nnGt+JpZ4CLfkAlyOMcdqzba8/s/V4mtwkr27lt+Mq/uRUeoWF1YTtFKjxzYBMUvUA9KhhhZUHmDbITzTbOynCCpqN7xtYsXU8txeY+RFmJfcw4ye2KmudN+3xpBC0SSqACzNgH6VUmTBjYuoVWyBWjNPHNF5ixAuxywQcfhSQpNxtyGVLaS20iL+7fYdpAOQcUt+jrOSqoityAvQfStS3tUWNbgsJFWQAxE8ge49KztUbfdM6/JtbIT2oWhUanNIqur7B5W5kPLH+7U8UkKwzIY2lkbAjfdjZjrx3pgBllVIgCzDPLYGahdgjJlCCOGI70bDtzaDpDtkUkhh0z61BKAm+TJPQ4zSsRztGQDkGp44XaNyqZA5FDZT01KUYP2hXHI9Kr65dvbF8AhCMjPrU77oX4yVB7dqg1qNbvTWZ85T5gR1qGXdKSfQxHmSUbVyXPNSSowjy2BgZ4qqL2AKjQxY8tTv7msDX/EAiiaOEYlYcc9B61UY3OTF4hRVnoVvEWq+ZK1vEct0cg9PatLwjEdwI6fSuJtVMkmS2WJr0nwpABEpxRV00PElUc7yZ29iNsQB5q/E2W2jpVS1Q7BWhbnypA20HHZhkVztlR2NJJT9lhEV4sO0YZBn168VUuCWkJMwmIAy/P9asG8wvEEH/fuq0snmPvKovqFGBTbIW58bRPgjmun0S/xgFjXJA81atZjG4INez8SseVTnZ2Z63p1wXUEGt22kPQnrXB6Bfh0UE/nXZWThgDniuGpCzOl9zZjYEc4GeapanEGjPFSpIPwptyfkPPFZIEcLq2YJlli4ZDkV33hW/j1O1RpG2lhtz71xPiBBlj1rO8Kaz/Z+oeRMf3UjcZ/hNa2ujsoVLOz6ntFt4f1S6iupbEi4Ntguo42rj72emKzvEFtqFnEIdShCM8QlRlYH5SOM4rY8M61Nps6TQ/NGw2yRlsCRfQ4rU1y6s9ShzHbSRz7QmWmLqEA6AEetJK50utUjO0loeZ2axsEOPmxg+laiIQ2AR1G2qTWZhuJtmdocgD2q9CSvyMQoONuKzaPQjW7FuxuJbd3UYJOeo6kmtK+nuBbosibWxltvBx7Vz9+ZWnWK3OXbkY7VoRfbW2vPPuZk2cDAAFI30bUtBJr50lWW3Mn+9jkf7NbsF95sdsxPmXEnICnt9O1YwtwV/TrwPxpFSWznjuLdV81PuqB1HuaauXJRnbudR5jPCEk2nd1p8UNl5wMqOECEHyzyW7da55NSeVWkOC/UxjtnnirenXK3EbvIzgA4BA70XMXSkkXms0EqgoQp+b5TzW5pjwppmoRLLGXljVCjx5J+bse1csdVxuO3Mo6A8Y+tZ1pqDgzMykzSMQRnA9aZUsPOpGzOsu7a1tn/dRlCF2sHbcM9yKqxtHFtjGVzyPc1lDxBCIyskW4bduGPQk9qab6ZWUbraQrjjBz9frTHGjNaSOhS78yPyYWJAO51ByM0sJjmO24LEZyxU849q5SxublLiUrEMO2G+fBJ9vap4Lq7tNyRtEYmzyRna3pmncqWGaukzcui9hKsZEhtt25gDgkY6VUjmCk4Zgh655Ipt3LMBEDMkgkXLY7GoFBxuPme54P4U2EIK2oPdT3SfZjESpOFAHU+1CSyPMkMUSx3AfJdjwKGR9wAXkHA5wf/rVXW6eG8topY8QByQwPXPY0jSyaskdEb6SOzntg+GuMBo8dx3psyt9mZJoWMqJ8joQRmshb17O4lcxuQy4UbgSvtVdnubiUrEHTCbiinhvY0GUaN9duol7Il9E5lhxOOjRghce9RW+rTxxLCYykgGC3Yr6ir8YKxtHG48onJC8c1WvLcXM4WUqGA+Zuwosb80WrNaDbO8QNIrAJnkSEfpVxLh8PJBIp8rk89TWVqOnq148FopYEqAWbgmmTaTqEV/JZrbBpjIFxHIMMR2z0qR2hLW5uXWsyXFyJb1mluW4ZW5IGOKRn+0lVC7NvLHP3q503d1a3CtJbkjftIcZx2xmtOe4keGXydkW4YAIz+VIh0VG3Ki7ayWdzP5UhKsGyVY8AVcJ+zTMIJiYiDgZ6D0rmUtdmzcFLMwbcRnGKsNezCN0aJQrneoXjBpjdG70Z1+l6iscV9C8IlkuIPKVmOCvOc1z7LIjbnJJBwxPpSabLPNeQSOAXc42qegFXbp98Ugf5XBIOO9K5ioeym7dSCztmvblLaA5kc4XPAz71burNre3eOf8A4+A+Gx0xT9HuWsbj7R5akoMAEdPcVHqF5JNJJLIvzMd3PpQ2jOUpupZbGSIiHCkHeCQAOlXBdNbRxwvxk8ZqvHdJI7MvG1cj61kaxqPnTR4yGHWlc6owdR2Z0E0Ec0gZHXceoHesbXbhYU8lQN4PI9qoJevEpKNgnoTVW8lE5+fmTvSbF7Fxd29DP1FUt7DbDwzHk+oNeaXjma7kbsW4+ldb4lv3hi2/xcqo/rXJ2sRdgSMk1vHRXPAx0r1OVGno1uZJlAHNeq+H7TZEo4rkfCmllmDsOK9K02AIgwK56krswS0saFsmFFWlIVwWVXA7HoabGvHy09gAKzLSL0UZkjD/AGa2VSMjc5Bx69aoX48u5KlUQgDhDkVZWT5IS8bFWUwkg/eHt71U1Jv3+3aybFC4brwO9V0M+p8ZU5Tg02ivVTPFNvRr3yXUE8Zr0XRb9XRRnOa8ijcqwrq/Duo/Mqu/SlUjzK6OqnO6sz1GKUHBzgVNKdyke1YlhdblBz0rVjlDrzwa4mrM1sc7rkZKnuK4G+JjuSw4IOc16Tq6bkPtXnmux7ZSe1bUnqXLa56P4G8QNe2gjlZRLFhSCevvXeWlyGOXyRjt64r5w0nUZdOulnhJ4+8PUV7F4a1pdStEeJ144KnrSnFxdztoVFVjZ7o07mby79t+QsnI+vernlxyuoYZ46g9Ko6qRuhbjcCT9KsWzg+XtOe5qLGyloS6Va+XeTysxbgBc81pFizFh8oAx061TtJMTTegA/GrQkXyVXoxNQ0dFObeo5WKuAQzZGc9qfIUCKCMk881B5oTGHXaGx1yKI5/PmclQUQHavqaR0Jma9qY7l2TdGww2VPIqbzJQ7sJWVmwAqY5PqauTwqwPlrg45qvGpBIKgcDjFB1wqXWo2FHkncxZkmI+Zj3AHOada25MqAyiItknjO30wPercUasMnP/AamuBGrt9mj8tCoB3HcfrmmP2pTuEVrQbQAAFAi6555pZbd4J9k0DQtgHY4wfr+NbOiCJ7u3W8LJbo3LRqCw/PrS+LdSn1Ga3+0SiX7OpjR9gViueN3qadupmq0udQS0KVtbQyBmdwoXLKVGctjj8KanMDLnapAJAHB5ogUv5ajGX454H1PtUlzE9lcSwZjfZzuibcrD1Bo6F82tr6haQNJKyws7yKpbGccAZqSPayhsHd/FnuT6Cq8VybYuypICem7r+NPWRsBjGQANwJ4xQgkn1LUeBzwrDg8Vm6zEphJXnbyPQmpHkLDczgJjJPqKS+NvLoDSxSEXCMcrjjb25qmSvdkmJHFJHbxTSxr846FQcA1ZsphbtFIoCtFypX17ZrOs7mSa3RpDxt4IH61ahumUMgGQwwwxwalFSvqmXDK07s7YUsckAdahurfKAxtgg80LJjIzyecAVIbtYXy6BgRg7hVGV2noULSSeNXIIYMT9a1bQKqozortnPcVVgAClgFAY8E9qnLkDaTnHAx/OhKwT97Qk1Mw3Mkj/Zoo4jwkSdE+lZ9hpcMpaSW4aNV/hIzU+cuMnIz0qW6WAxQiHeJQCJgT1OeCPwoYleCUYle7jjzL9kLiJWwhfkkehqLT5rWKRYLyJJk8xXPmcHA/h/GpE+RdiHvk5/nVeeOK4mwrJJCwJBYY+apZvFXXK9jTvpbPy4RpkDQTRA73/56ZOeh9KnmXzlQFdvQk+tZdhC8coS4Yk9cf0q8xZZNjAgHlc9xUGTio6LoPmu1VWtokXc2G3Hrx71g6pqgYKqSsSDyccfSofFFzJa22zBLSNhXUdKy4YiygszAkcgdDS3NqNOKXMyeOdmBOCAM4wcZ9qp4lmfe4I9j6VpJAu0o33B81V4gcYRWRi2B3yKLGvtlG9ivJCWjA6Dsc1nXbeUCVGXI5IrbndVh3vjIPSuX1nUVijmmJxn5YlHdj/hTUbnLWxfLFvscnq9y99fHc25EwqjsBWroGmG4mTIOM1Q0mzM8yjGSeteo+HNNWGNSVyaqcrKyPnU9XJ7sv6Lp4ijRQOPpXTwQhQMdKis4QowBxVxBtBx2rnLSAKVHFRPvZgFBLdgKkZsc9c1GXKuGBII6YoHYtIiz28XmiZWRdvyxlgRmqGpyl5sbXUKoUBxyQB1NXmeOKCHzJboFl3bY2AAGarajDHiSRJZXZArHzOcqen/6quxjezPjMZooFFemeMA61PbTGKQEHvUFKKa0GnZ3PQPD2rCTajHnFdbbzhgMmvIdMvDbzqSeK9E0q+EsQOc5rGrBbo7IT5kbV3hkIFcZr9rvDEDn0rry+9fasvVIvMQ8dqxj7rNltY80kyrEenFavh3W5tGvBLGN8Z+8hPX/AOvUGr2phmJA4NZ1datJGHM6cro93fVbTVNMsby0UIGT5wTyT3qxYT8qMfL0B9a8a8PazJYSeVI2bZzyD/CfUV6dpt2sUYZj5iHDKymueUHFno0qsZw03OrS3kjmDg5DqR9Kv2SQyK3nkYB6+tclda5I0we1fMeOnrStrZm2MhxIOoPSsWdtKM5Kx1U6lJmDbRbgcKB1phDbXEYjDDkdqq6XqdrqChbpgswzhSePwqxceXFHH5iknpmkdF2/dZKUkSLc20kDJIaoYpSWIwef4jyKFm3plmBB4OVqvMzGSNY227jgehoZcXY0EcsPmB9ABUowfkHX0zVa3BZCWADA9fX6e1WIboRw+WAp3DnjP5elBfN2HxlkJKlgPWo73HkZYn/E1IJc54BwMn2qN43uXVEysbdWPSqvoUpa3YgdI7eFopGc4+YMvA9qYG3/ACkAyDgY5B9qd9mWO4WJGQop+8R1q6Y0gzsj9yx4A+lJuxfOkR2wW2njuJyjqufkf7oyMUlvewp5hKI8WcKzHjA7e9UrtprpSy7CiruC5yapfa3Cxjy0ATplfT6UrlqHMtdye4uxNNI6oAp6An7q+1IIW+z3GY3f93k+Xnv3NNhTEnmyRA5JODU8cjxSkg+WpBznmncc5JLliO8PYt4HFxbrKrJgbj93Pce9OjjWQbtpHJII9PeqkKThmRpAyD8Dz2rVtlAIUbVA45OSPamjGUrO/ce6W6QxpFGDLkkuTy2e1VZrdw8atKCr4Pyn7vsatyqyBiYwARzgZNRWkQur6COSeK0hd9plkGQnoTTYoy0uaMVmrukUIZy52qFHeq88bxSssihdp2t/s44qm2pi1vZbd2ZlD4WaPoxHcfWr4dJhgk5Iyf8A69TcLSjvsMvLhrgB5vKEnC/ugANo6ZqqZGbqC2KfdRhGBCYyeo7+1MJwWBBVj09qL3LVktAlfcAcFSOnNLbJHIV+0AJEpBdY+CR7VXlkRCBI6nccD3NPEzRPnarDHApNlX0sjS03UIbGKcrarciRWRfNOCme4PrVOK/EpkUsCqnA9qjnIeMAxhAedwPWsuV/s7M9vgbhx6E1O5moxbb6sdqD28kcpZweMAk9KrWi4tfmKnHTHeqd0rXERIVMr98+9WbbC2qASBn/AFzTSKqVIxjZPUvchgcAoRg1TvbqKBcD5TnK4HX1qC8n8uJnLAFDXN6nqybGBcAA53MelXFXOGpU63J9R1CPY+5sAknOelcbdXbX91uxiNeI19B/jVa/v2u3MaEiPOST/FVzS7Uu6qBVtcqPOq1fay5VsdT4Ssd7qxFenabbhEA9a5zwvYCKFOOTXb2kGFFcsndiW5LECBxTwdzGnom3tSsAMnFSURuDjjFVnzux0qVnIbvioZGGKYi+kqwQR/aZVwwyimLfgevtWXq1zMrPE7h1fD7gMbhjj/8AVT3u08pEngEuwYU7ipx6HFUtTdjMGkKgsilVXoFxwKoxZ8jHrRU88RQ1BXpnkNWCiiigQoODW9oOptDII3f5fWsDNKjbWzTXZlQlyu565p86yIDnIPNW5UEiHvXDeG9UyRFI2COldpbzh0HvXPOHKzvjLmV0cxr1lvBIFcbNGY3IYHNeoX8IZD71xOtWWCzqKqnLoKpG6uYQq7Z6pd2u0RTsFH8JORVBuDg0A81vozmUnF6HZaX4gWR8MPLkIwR2augsZkkI3NsYnPtXlwY1t6ZrJhAS4ywHAbvWMqS6Ho4fHPaZ6HJ5lvMjRfMRyCD1rai1lpvJRgUAXnnvXF2mqIyfI6SoRwwPK1aF4PMDg/MO4rnlDU9anXUldncQ3PyAkMFK7uucmoZLh5IBMNm7cCCD09sVjWN6vlqTIGJ6j+lTeZGGZldiM5ABwKixtGSZuxzXiMocISThdrdK1zKrAk9MY44NcrBdbSoGHYjJw3H1rVgvFIG08dcDsaCtbmv8u3aMoOowe3emLcSSkiNRsUYL7scfSqcF0iOWdc5OeBnj0qeKeKUBoQEB55OGB+lFx6otRJuQlSC/bd0/OprolwluX+V2GVB/OiGFPLG0sADyc8GornE26JYiyt3HA/Ole5PPczr8ypeywWbBY0XkYycexpLRchWXdnryOv1pqNB5rR3EG+4XJKKfu56c+lXraSJI2Dw4YjCjk7fce9NI2daysNfGSCPn/vY4FKbfzIGdpECdckUjSlu2SeMDvVWeWKJWMzquOityMfSmZOTY9Nu9UunRo+i7Tgn8akmlEcxAbK9QRyawYruKKWVWtj5THMYPUA1Pa3UMSsrhkHt0p2DmsdF9qllADS7uMYXr9aqXijJy7q5HG4YFU11GCKAGOZjx8wY4I/Cie6aeJJUdX4OVUZI+vpSZpTnbUpTS+WQH3yxN1AOPxrb0t5o4mKQS+Ux+YsQdtYF1cyxb0QK0Z656/lUVhrVxpyNGZM9NjAZAB7VLN5vnjZHZSyu8qNG2VTuRxVEXUskzxtAYwh4Ynr71T0zWYpJWZnZFPYrxmteX96gXhyw4qdTn5uXRopm4++QS3GPYH1p0avMSqkemR39qgvVZcsoAxjkDoPWpNO1x9OUgWzSZOUfGOn1qiKlVpXiMv5DDN5OGWUDaQTgg/SqNzJI0W07QFIZfQ4qrqWqpe6hLeSloix4UdfSse4vSIXyxJ6HJ7U0ifaOyvua5vDGriPaGfnkZFVri4ltLcXMvl7JGYBQw3ZHt2rGfU2ZyseWDYHA5PtWDrWp/ZJApdZbkHLR9Qv1960ijkq1VHc3NQ1COOza7vAViz8iZw0x9vb3rhdRv5L64LsAiZwI16AVXu7ue9mMtxIzufU8fh6U61iLMPWtVHl3PMqVnUfkWbGHc3I/Ou58LWW+VWYcCuc020MjKqgn2r03wxpnlRoWHzGuatK+htTjyxudTokIULx2ro4l4GBVPT7URxjFXlBHT86wKEcH0qInA5zUx96pzuV4HSgY2VhVVpUVgZFLIOoBwaWR81AIzNKkSEAucZNNEt2HzXVhz/o83P/TX/wCtWZqNytxMrRqyKqhACc8AVZm+wZK+dcHtuCDH5ZqjeQGCXaHDoyh1YDG5T0qznbTPnvVbDbllH5VgSoVPIr0vUrLO4betchqtjsJIXBrtpzurGFandXRz1FSSLg1HWxxNWCjtRRSES28zRSBlOMV2+g6qsyKrnDiuD+lT2tw8EqspwRQ/eVma06nLoeso6yp61nanY7o2461Q0PVVnjUZ+YdQa6ZQJo8nBGK55RcGdilc8y1SwMMhwDg1lkYr0XVbFWVuK4vULQxOSBxW0J3MqlPqjNp4pCuKDWhiia3uJIH3RMVNa1rrbqNsy9e61h0UnFM0hVlDZnbWOoxStuRunboa2IrxnXHbHFeaK5VgQSCO4rV0/WZIMLLl17HPIrOVJPY76ON5fiO/juQOCQCeh7VYs7kNIqs+Nx6setc3bazHcR5BQkcHsfyqxFJ5z7VZR6ZNYOk0enDFRlsdrG4cGFpVDhhkZyCK2pdTcwW8MkCYhztKoAzZ9+9ee2mrTWYKxhGJJ5POK0NN1pDN/pjsV7Efwn2qHFl+0vqdtqd5JFZrIjSBCRlCMf8A6qxv7Ula42xObWMrgqcv/OqGparFNaH7Pco6ZwUf7/PYGsr7eoGUPzZxzwVH1pONiqc1bU6zS7yJPNFyN8rKSzN+hGP5VeWcnhFdlB7ISPzri1vkMSttiBOB8rYYe9WrfxDNbKiozMgXABPWiw27u6O4RDGdyqG9s81Tk/fzEyIiAPnc1c1H4ikNx5kkZDF87V4JHpWjcapBMGjuY5Yg68A9zQYSk4vUr3V9azXAZ8iNARx3Pr9KhnuI7dtzj5eNrdQRWNrd6ryLFAuAOm0dayHmfoZFXHGGbAH51ootg6iR2i3FuYhKZg6njb3H1qP+0oYo/wDRXkWUEbx/CR+NcYl9bjcrXMKsvbdkGmvqNuqh0uIhzjG7mnyMn28O52k2oweXJlpElbB5Gc1nT3jSReU7hVUHbkZ/WsS31hgCPOhZGGCGYdP6VHNrMZURmaGOI9Oc4+tL2bKWKiup0MmoLKyhkHmxqFKxjAf649K07DX2jLI7yOVHyjbzj0zXn02sW6cRyAlf4lB5og16GJ97bZuxDqTR7El4yFrXPT59aUwDcqqx+Y5OOPT3rDvdbec7WVo4xz8vNcpJr9qyjc53A/wIT/Os2+14vI32dDtPQtx+gpxpMxeKgtjq5r/Cl7dSsaj5nY/KKw7/AF2Lf98znp8nC/nXN3V9cXQAmlYgdFzgD8KrDp7VqoJHLUxcpfCb0niS6VHSzjjtg3G5Blx/wI1i7mdiSSWJyT3pFUlulXba2LnOOtNpR2OZuU3qR28JcitqwsyWAA5qWwsGYqFUk13fhzw4XZWkX8K5qlU6IU+XWQeFtEYlXdefevSNKsljUZA6cUulaUIEXK1sxRomCOM9K5tXua3uPiiKpgdKUAgdKk3gCoHkw2c8UFJDZHqlN8zGpZ5gD7VTmmQLnNAnoQzEfSqgkl89DBkyjldo5zSzy8daou7B18snf229c1SRhKRpS/aTljpUbMed3kt/KsrUJJjOxulKyEDgrjA7YHpVu7i1Gd97AI5AyolAJPrjPBrndSuZIZHSfcrrwwY81aVzExtRswQxxXLalZ8EEZr0a5t8g8cVz2p2WcnFTCdjU8q1WxMZyo49KxnXBr0PVLEEMCOK4/UrMwsSBxXdTnzI5q1LqjJopWXBptaHELmikozQBasrl7eZXU9K7/RdVWaJcMM15tmrljdyW8oKnA9KGlLRm1OpbRnqsqidDj+VYl/pvmZ+XGfSn6HqaXEYG4ZPUV0CKkyA5rnacWdikmjz+60UnlRjFZVzYSxE5XivUZrWPcBjk+1UbrSPMGQopqrYPZxkeYlSvamkGuu1DRNrHC4NYk+nyxMcKT6YrVVEzKVFozKAamkt3XqpBqMoelWmZcrQKxXkE5+tWor+ePpISPQ81VxSU7jTaNmPW5QDuQZ9V4qQayCcuGPsOKwwcUueaVka+2n3OhGtxBDtRyc9DSpridTGxPoa50njNCnINDimUsTNdTo/7bT+44z2qyviKLy0U+b8p4B7CuVBPp+NKKXIiliqnc7CXxDDIyuzP5i87uvNQ3HifcdyCaSUjDGRuK5YHHalHIxRyIbxM31NO71m7uTy/ljsEGKoPI7n5nZj3JNMwQRjvTgnHf6U0kjJzlLdhk9jQDxzTgh/yKAhFBI0HH40v9ad5ZODjrSiI9OtAxh/zilp4iY/SnCIntSuFiLJ9KXbk9+KnjhZjjBqwlmzdAalySGotlEJnsTViOAsQNvFaUNiOA1aFtZE4CqfyrOVVI2hRlIzbWz6ZFb2l6Y8zqqKSCa09L0Ce4YfIQPpXoGgaDHbAbgM+9cs6tzpjTUPUqeHfDioqsVyxrvtO06OJR8oyKSytxEoCrgVoE4X0NZiabY/aE6DpUZIJyetMEhJxk02QqDyePakWo2FlcAEKaqSMc9alZhiqk7AE5zQVewyeQAEH8azGChsj8qnnfIqhLJt64ppGE5DbiTiqkd59mu4psbghyR0zUF1cgA5PNUbfUIodQhknP7pXBYnnHvirSuc8mXL1tOT5nu7iPPO14Pm/PPNcp4r1hZJ96q6RrGqL5n3mAHBP1qxq3iBFmntNWulnt2PE6ncYyejKfT1FcB8QNXE+pRx288c8a20S+ZE2VYha6qdPuZuSjqz3KWLIPSsu8td2RjiuhePP0qncRdcivOOto4TVLEYbiuS1WxDAgrXqN7ahk5xmuX1Sy61tTm0S9VZnlF/amFz1x2rPYV2+sWG4Egc1yN1AY2IIxXfCXMjhrU7bFSig9aKo5gpR1pKKALtheyW0qlWwK7zRdVWZFwa82HWrlnePbOCpp2UtGbU6ltGewRTiRQBitC0UEAVwWi6wsqgFvm9K6qzvgcHd+dc06bR1xd1obb6VFcgkqOaxtQ8NdSgFdFpt0rgDNbKIsoGRxWOqLUmjyG90J1zujzWDdaQy5wMe2K93uNOjcfMoNYWpaBHLkooB9apVGinyy3R4nLYSITkZqu0DA9K9K1Dw/JGx2rWPNozgnMf5Vqq/cl4fscX5Zz7UnlnPSuqk0rH8ByKiXSxn7lX7ZE/V5HN+WaURkdRxXSHShj7pp6aWB/AaPbIFh5djmhCT6inrCcdK6YabnACHHpTv7LI/wCWZ/Kl7dD+rS7HMiBjjjJqWO0dugOa6RNOIPEZrRs9GmlI2xnNS65pHCvqcrFp7H6Vaj03I55/CvRdM8IvJtMgro7XwjEoG5M/WspV2V7KCPHBpXqmKc2mc/d5r24+FYQP9UtM/wCEUiOf3QzU+2ZXJDseJDTR3X9KcNOA/hNeznwhCTnygKlTwfCSP3YOKPbMfJTPFhpx7Ifyp39nc/cP0r27/hFIVGBEufpTD4Thz/qxSdRjUYdjxlbFgB8h/Kr9rpM0zAJGTXrkPhWEdIxWhbaFDGcKoBFS5tl+6tkea6d4WeQjeMV1mm+F4o8HYPxFddFYpGOMVYjQAdKl67ju2jKtNNjhAAUVoQ2oVsgHHarQUAcj8acrgduBSBIlh2qgHemyNt7ZqB5cHrUUkozz+FAWsSSScnFMkbIxVZpRntUZlxz3pA2SlynWqlxMMGmyzcdaz7q4C5qkjGUgurgLkVkXV2O5wKivbtRnLVz19egEndxWkY3MG7lu+u8qct0rmtTvzvWOIF5HYKqjuTVXVtXWJTuYE1ycOsZ1iGWZysIJVmHVQQRn8M5rqhT6mU5qKLuqLBczmF7+TzQC26O3LRADqd2ckDB5AxXM31vLaXLwzAb17qcgg8gg9wRzXWrayjU7W9C3rSQRoqpDGGhcKuBtkztCHGTn1Nc5r0sb3cccTrIsEKQl16MQOSPbPA9hV3OOUnI+qmAOarSqMdKKK8k9llC4RSDxWDqESEciiiqW5kclqkahmAHFcfrUEYydvPWiiu2juRU2OZkGGNMNFFdDPNluFFFFCJCiiimBZtZXjcFDgiuu0W8mdV3NmiiqfwnVQOz0ed9wGa7GwkYqOaKK4Z7nSzUDFlyaaoDDkUUVky1sV54I2ByoqrJZQMDmMUUUDKr6ZandmIVEuj2e7Hl0UUGibIJtMtVkwsYxViLSbQpkx80UUkVdk8el2ivgRjBqb+y7Tb/qhRRQO7EGl2gcfuhWnZWUCbdqAUUUgub9rDGqjCiru0Z6UUUyB20Y6UsSjJ4oooKHYHPApV78UUUA9gABHPpShRxxRRSAY3Q1CThgaKKCkBY0uSGoooLQjk4NNLHIHbGaKKTAikJqBiSmT2oopAyuTnrUUrnHWiiqRnIozSNt69qxb+Zwh5ooq4nNI5m7nkYnJrm9VuJEjyp5ooreBLOH1C4kllbe2cGqDdaKK6WcMwEjhCgdth6rnim0UVJmf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_31_19959=[""].join("\n");
var outline_f19_31_19959=null;
var title_f19_31_19960="Hand-foot-and-mouth disease - buccal";
var content_f19_31_19960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58566%7EDERM%2F71314%7EDERM%2F53423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58566%7EDERM%2F71314%7EDERM%2F53423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hand-foot-and-mouth disease - buccal mucosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small ulcers are present on the oral mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hand-foot-and-mouth disease - tongue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small ulcers are present on the tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hand-foot-and-mouth disease - foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple vesicular lesions on an erythematous base are present on the foot.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_31_19960=[""].join("\n");
var outline_f19_31_19960=null;
var title_f19_31_19961="Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease";
var content_f19_31_19961=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/31/19961/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/31/19961/contributors\">",
"     Richard C Becker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/31/19961/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/31/19961/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/31/19961/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/31/19961/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/31/19961/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelets play a critical role in normal hemostasis, preventing continued blood loss after vascular injury. However, they also contribute directly to pathologic vascular thrombosis. This relationship constitutes the rationale for the use of antiplatelet agents in the treatment of coronary heart disease (CHD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4167?source=see_link\">",
"     \"The role of platelets in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three intravenous glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors are currently available for clinical use:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    . Abciximab is a monoclonal antibody directed against the receptor, while tirofiban and eptifibatide are high affinity non-antibody receptor inhibitors.",
"   </p>",
"   <p>",
"    Antiplatelet therapy with intravenous GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors has been evaluated in patients with acute coronary syndromes and in those undergoing intracoronary stent implantation. Dual oral antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a platelet P2Y12 receptor blocker has decreased the role of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    therapy in these setting, although it continues to be important in some subgroups of patients with CHD.",
"   </p>",
"   <p>",
"    This topic summarizes the early trials of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors performed before the routine use of intracoronary stents in patients undergoing percutaneous coronary intervention (PCI) and P2Y12 receptor blocker therapy in patients with acute coronary syndromes or those undergoing stenting. These early trials helped to establish the concept that aggressive antiplatelet therapy (in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) could improve clinical outcomes in many patients with CHD.",
"   </p>",
"   <p>",
"    The role of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors in patients who receive currently recommended treatment with dual (oral) antiplatelet therapy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE PLATELET GP IIB/IIIA RECEPTOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet activation can be accomplished with a variety of pharmacologic and mechanical mediators, leading to platelet adhesion and ultimately aggregation (",
"    <a class=\"graphic graphic_table graphicRef76852 \" href=\"UTD.htm?37/19/38203\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76572 \" href=\"UTD.htm?14/27/14783\">",
"     figure 1",
"    </a>",
"    ). The ability of platelets to adhere to abnormal surfaces and aggregate is mediated by surface membrane glycoprotein (GP) receptors that can be expressed in greater numbers with platelet activation and serve as potential targets for therapy.",
"   </p>",
"   <p>",
"    The platelet GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptor is of particular interest because of its central role in platelet aggregation. Following platelet activation, GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    undergoes a conformational change rendering it competent to bind protein ligands in general and fibrinogen in particular [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/1\">",
"     1",
"    </a>",
"    ]. This allows for a bridge to be formed between two adjacent platelets.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ABCIXIMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     Abciximab",
"    </a>",
"    is the Fab fragment of the chimeric human-murine monoclonal antibody 7E3. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7318?source=see_link&amp;anchor=H8608107#H8608107\">",
"     \"Structure of immunoglobulins\", section on 'Antibody fragments'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pharmacokinetics and pharmacodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following intravenous bolus administration, free plasma concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of 30 minutes, probably related to rapid binding to the platelet GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptor. Platelet function generally recovers over the course of 48 hours; however, abciximab remains in the circulation for up to 10 days in the platelet-bound state. Upon completion of a constant infusion, free plasma concentrations fall rapidly over the next six hours then decline at a slower rate.",
"   </p>",
"   <p>",
"    Intravenous administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    in doses ranging from 0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    to 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    produces a rapid dose-dependent inhibition of platelet function as measured by ex vivo platelet aggregation in response to ADP. At the highest dose, 80 percent of the platelet GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptors are occupied within two hours and platelet aggregation is completely inhibited. Sustained inhibition is achieved with prolonged infusions (12 to 24 hours) and low-level receptor blockade is present for up to 10 days following cessation of the infusion. Platelet aggregation in response to 5.0 mmol ADP returns to &ge;50 percent of baseline within 24 hours in the majority of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     ACS patients undergoing PTCA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of randomized trials were performed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    in patients undergoing percutaneous coronary intervention (PCI) primarily with percutaneous transluminal coronary angioplasty (PTCA) in whom P2Y12 receptor blocker therapy was not used. In a meta-analysis of over 5400 (predominantly) acute coronary syndrome (ACS) patients enrolled in the EPIC [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/2-4\">",
"     2-4",
"    </a>",
"    ], EPILOG [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], RAPPORT, EPISTENT [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/7\">",
"     7",
"    </a>",
"    ], and CAPTURE [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/8-13\">",
"     8-13",
"    </a>",
"    ] trials who were treated with PTCA, abciximab significantly reduced the 30-day incidence of death and myocardial infarction (hazard ratio 0.52, 95% CI 0.41-0.65) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9300137\">",
"    <span class=\"h2\">",
"     STEMI patients undergoing PCI with stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes after either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    or placebo were evaluated in several randomized trials of patients with ST-elevation myocardial infarction (STEMI) undergoing primary PCI with (primarily) stent placement, including RAPPORT [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/7\">",
"     7",
"    </a>",
"    ], ADMIRAL [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], ISAR-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/17\">",
"     17",
"    </a>",
"    ], CADILLAC [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/18\">",
"     18",
"    </a>",
"    ], and ACE [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/19\">",
"     19",
"    </a>",
"    ]. In a meta-analysis of these trials, abciximab was associated with significant reductions in mortality at 30 days (2.4 versus 3.4 percent with placebo) and 6 to 12 months (4.4 versus 6.2 percent) and in reinfarction at 30 days (1.0 versus 1.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition there was no increase in bleeding. This analysis provides support for the concept that abciximab is beneficial in reducing acute ischemic events during primary PCI with stenting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9300316\">",
"    <span class=\"h2\">",
"     Stable patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;As presented above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    reduces the incidence of periprocedural myocardial infarction (MI) and death in patients with acute coronary syndromes undergoing PCI. Two trials, EPISTENT and ISAR-REACT, evaluated outcomes comparing abciximab to placebo in predominantly stable patients undergoing PCI with stenting and came to differing conclusions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EPISTENT randomly assigned 2399 patients undergoing elective (about 40 percent) or emergent coronary intervention to therapy with stenting alone, stenting plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      , or PTCA plus abciximab [",
"      <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"       Ticlopidine",
"      </a>",
"      , in addition to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , was given to all patients receiving stents. The 30 day and six month incidence of the primary end point (death, MI, and need for urgent revascularization) was significantly lower with the use of abciximab (10.8, 5.3, and 6.9 percent, respectively and 11.4, 5.6 and 7.8 percent, respectively) (",
"      <a class=\"graphic graphic_figure graphicRef51992 \" href=\"UTD.htm?0/37/607\">",
"       figure 2",
"      </a>",
"      ), primarily because of a reduced incidence of death and large non-Q wave MI (",
"      <a class=\"graphic graphic_figure graphicRef59212 \" href=\"UTD.htm?38/3/38973\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In the ISAR-REACT trial of 2159 stable patients undergoing PCI with stenting (90 percent) and treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and a P2Y12 receptor blocker, patients were randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/23\">",
"       23",
"      </a>",
"      ]. At 30 days, there was no difference in the incidence of death, MI, or urgent target vessel revascularization between abciximab and placebo (4 percent in each group). Major bleeding complications occurred in 1 percent of each group. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H6#H6\">",
"       \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Efficacy and safety'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9300106\">",
"    <span class=\"h2\">",
"     Patients not undergoing reperfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The GUSTO 4-ACS trial evaluated the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    in 7800 patients with unstable angina or NSTEMI who did not undergo revascularization; patients were randomly assigned to abciximab bolus plus 24 hour infusion, abciximab bolus plus 48 hour infusion, or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/24\">",
"     24",
"    </a>",
"    ]. The primary end point, death, or MI at 30 days, was the same in the three groups (8.2 and 9.1 versus 8 percent for placebo), as was the rate of revascularization with angioplasty or CABG (30 percent of patients in each group).",
"   </p>",
"   <p>",
"    This lack of benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    in the GUSTO 4-ACS trial persisted at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/25\">",
"     25",
"    </a>",
"    ]. These findings from GUSTO 4-ACS are different from those observed in other trials with intravenous GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors, in which benefit was noted in patients who received medical therapy alone, with additional protection in those who underwent revascularization. The reason for this difference is uncertain but may be related to dosing and the degree of platelet inhibition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     TIROFIBAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     Tirofiban",
"    </a>",
"    is a nonpeptide inhibitor of the platelet GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptor and interferes with platelet aggregation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a dose-dependent inhibition of ex vivo platelet aggregation within minutes of bolus administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    and this is sustained during continuous infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83657274\">",
"    <span class=\"h2\">",
"     UA/NSTEMI patients undergoing PTCA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    (bolus plus continuous infusion) to placebo or to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in patients with unstable angina or NSTEMI scheduled to undergo PTCA and in whom P2Y12 receptor blockers were not routinely used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The RESTORE trial randomly assigned 2139 patients within 72 hours of presenting to the hospital to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/27\">",
"       27",
"      </a>",
"      ]. The primary composite end point (death, MI, angioplasty failure requiring CABG or unplanned stenting, recurrent ischemia requiring repeat PTCA) at 30 days was reduced by tirofiban (10.3 versus 12.2 percent in the placebo group).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further analysis of the data showed that patients who had evidence of minor myocardial injury, based upon positive serum levels of troponin I or T, benefited from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/28\">",
"     28",
"    </a>",
"    ]. Among the 28 percent of patients who had elevated serum troponin I (&ge;1",
"    <span class=\"nowrap\">",
"     &micro;g/L)",
"    </span>",
"    on admission, tirofiban significantly reduced the 30 day risk of death (1.6 versus 6.2 percent for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ) and MI (2.7 versus 6.8 percent); this benefit was seen in patients managed medically or with revascularization (",
"    <a class=\"graphic graphic_figure graphicRef75639 \" href=\"UTD.htm?14/32/14862\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The PRISM-PLUS trial randomly assigned 1915 patients to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , or tirofiban plus heparin [",
"      <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/29\">",
"       29",
"      </a>",
"      ]. At seven days the frequency of the composite primary end point (death, MI, or refractory ischemia) was significantly lower in the group receiving tirofiban plus heparin compared to heparin alone (12.9 versus 17.9 percent), primarily due to a reduction in MI.",
"     </li>",
"     <li>",
"      The ADVANCE trial evaluated the potential benefit of a higher bolus dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      than had been used in the RESTORE, PRISM, or PRISM-PLUS trials [",
"      <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/30\">",
"       30",
"      </a>",
"      ]. A total of 202 patients (56 percent with an acute coronary syndrome) were randomly assigned to tirofiban or placebo. At six months, the primary end point (death, MI, target vessel revascularization, or bailout use of a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor) was significantly less frequent with tirofiban (20 versus 35 percent). The benefit of tirofiban was significant among patients with an acute coronary syndrome but not among those with stable angina.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83657522\">",
"    <span class=\"h2\">",
"     ACS patients treated medically",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies have evaluated ACS patients managed with medical therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The TETAMI trial randomly assigned 1224 patients with an acute STEMI who did not undergo reperfusion to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/31\">",
"       31",
"      </a>",
"      ]. At 30 days, there was no significant difference in the incidence of the combined end point of death, reinfarction, or recurrent angina (16.6 versus 16.4 percent, respectively). As mentioned above, the patients in the PRISM trial",
"      <span class=\"nowrap\">",
"       (UA/",
"      </span>",
"      NSTEMI) treated medically derived benefit from tirofiban if they were troponin positive.",
"     </li>",
"     <li>",
"      The PRISM trial randomly assigned 3232 patients to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      and PCI was discouraged [",
"      <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/32\">",
"       32",
"      </a>",
"      ]. The primary composite end point (death, MI, refractory ischemia) at 48 hours was reduced significantly with tirofiban (3.8 versus 5.6 percent in heparin treated patients). However, at 30 days the composite end point was similar in the two groups (15.9 versus 17.1 percent), although there was a significant reduction in mortality (2.3 versus 3.6 percent) (",
"      <a class=\"graphic graphic_figure graphicRef68499 \" href=\"UTD.htm?27/52/28493\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83657537\">",
"    <span class=\"h2\">",
"     STEMI patients undergoing primary PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TIGER-PA pilot, On-TIme, and On-TIME 2 trials evaluated angiographic or electrocardiographic variables but not clinical variables [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/33-37\">",
"     33-37",
"    </a>",
"    ]. The three trials generally showed that treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    improved these outcomes compared to placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83657661\">",
"    <span class=\"h2\">",
"     Stable patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, stable patients in the ADVANCE trial had better outcomes with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    than placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     EPTIFIBATIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"     Eptifibatide",
"    </a>",
"    is a heptapeptide inhibitor of the platelet GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptor and interferes with platelet aggregation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Pharmacokinetics and pharmacodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma half-life of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    is 10 to 15 minutes and clearance is predominantly renal (75 percent) and hepatic (25 percent). The antiplatelet effect has a rapid onset of action and is rapidly reversible. Boluses of 180 or 135",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    produce greater than 80 percent inhibition of ADP-mediated platelet aggregation within 15 minutes of administration in more than 75 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     ACS patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IMPACT-II trial of 4010 patients undergoing elective, urgent, or emergency PTCA who were randomly assigned to two dosing schedules of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    or placebo did not show a benefit from GP",
"    <span class=\"nowrap\">",
"     IIb/III",
"    </span>",
"    inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/40\">",
"     40",
"    </a>",
"    ]. However, benefit was found in the PURSUIT trial of almost 11,000 patients with unstable angina NSTEMI. In PURSUIT, which included patients who were managed medically or with PCI, eptifibatide was associated with a significantly lower 30 day event rate of death or nonfatal MI (14.2 versus 15.7 percent with placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/41\">",
"     41",
"    </a>",
"    ]. The benefit with eptifibatide was equivalent in those who underwent early PCI or were managed medically [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/42\">",
"     42",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Stable patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ESPRIT trial randomly assigned 2064 stable patients to placebo or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    immediately before PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/43\">",
"     43",
"    </a>",
"    ]. The trial was prematurely terminated because eptifibatide reduced the primary end point (48 hour rate of death, MI, urgent revascularization, or need for \"bail-out\" GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor) by 37 percent (6.6 versus 10.5 percent for placebo).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h1\">",
"     META-ANALYSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses have evaluated the use of intravenous GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors in a variety of settings related to coronary disease. The impact of the intravenous GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors on clinical outcomes was assessed in a pooled analysis of 21 trials involving various groups of patients with ischemic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/44\">",
"     44",
"    </a>",
"    ]. The GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor significantly reduced the combined end point of death, nonfatal MI, or urgent revascularization at 30 days in the following groups of patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those undergoing a PCI (7.8 versus 11.6 percent for placebo, relative risk reduction 33 percent)",
"     </li>",
"     <li>",
"      Those with NSTEMI (11.4 versus 12.8 percent, relative risk reduction 11 percent)",
"     </li>",
"     <li>",
"      Those with an STEMI treated with PTCA (3.9 versus 7.8 percent, relative risk reduction 49 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83657882\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83658977\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary concern with antithrombotic therapy (and antiplatelet therapy in particular) is the increase in bleeding risk. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40089?source=see_link\">",
"     \"Periprocedural bleeding in patients undergoing percutaneous coronary intervention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H39#H39\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Bleeding risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rate of bleeding between GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor and placebo has been higher with the former in some [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/7,8,26\">",
"     7,8,26",
"    </a>",
"    ] but not all studies performed before the routine use of dual oral antiplatelet therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/32,39-41\">",
"     32,39-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether this includes an increased incidence of intracerebral hemorrhage was addressed by a pooled analysis of 14 randomized trials involving almost 28,000 patients treated with one of these agents or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/45\">",
"     45",
"    </a>",
"    ]. The incidence of intracerebral hemorrhage with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    plus any GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor was similar to that seen with heparin plus placebo (0.12 versus 0.09 percent, odds ratio 1.3), and there was no difference in incidence with a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor alone compared to heparin alone (0.07 versus 0.06 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83658992\">",
"    <span class=\"h2\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia, at times profound, has been observed within 24 hours, and occasionally within several hours, of administration of a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor. This subject, as well as the management of thrombocytopenia in patients treated with these agents, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/21/24918?source=see_link\">",
"     \"Thrombocytopenia induced by glycoprotein IIb/IIIa inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83659000\">",
"    <span class=\"h2\">",
"     Allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been concern that since a first course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    can result in the generation of human antichimeric antibodies, readministration might lead to serious allergic or hypersensitivity reactions. However, the risk of such reactions does not appear to be increased [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h1\">",
"     COMPARISON OF AGENTS FOR PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of eight prospective trials involving 14,644 patients undergoing a PCI compared the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/48\">",
"     48",
"    </a>",
"    ]. Although certain differences were noted, a major limitation of this analysis is that each of the trials compared one of the drugs to placebo; none directly assessed the drugs against each other. Thus, differences in study design and end points might have contributed to the differences in outcome. In addition, as mentioned above, these studies included patients treated with PTCA or those who did not receive P2Y12 receptor blockers. Our interpretation of all available comparative evidence from these early studies is that at optimal doses, abciximab, tirofiban, and eptifibatide have comparable efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/43,48-55\">",
"     43,48-55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h1\">",
"     COMBINED THERAPY WITH FIBRINOLYTICS AND GP IIb/IIIa ANTAGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of relatively small angiographic studies evaluated parameters of coronary patency, including early TIMI grade III flow, after either fibrinolytic therapy alone or in combination with GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor. In general these studies show improved flow with combined therapy, but higher bleeding rates. These studies included IMPACT-AMI [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/56\">",
"     56",
"    </a>",
"    ], TIMI-14 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/57-60\">",
"     57-60",
"    </a>",
"    ], SPEED [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/61\">",
"     61",
"    </a>",
"    ], INTRO AMI [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/62\">",
"     62",
"    </a>",
"    ], ENTIRE-TIMI 23 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/63\">",
"     63",
"    </a>",
"    ], and INTEGRITI [",
"    <a class=\"abstract\" href=\"UTD.htm?19/31/19961/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical efficacy and safety were more completely tested in two large trials, GUSTO V and ASSENT-3, which are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link&amp;anchor=H23#H23\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\", section on 'GP IIb/IIIa inhibitors and reduced dose fibrinolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H277514761\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Platelets play a critical role in normal hemostasis, preventing continued blood loss after vascular injury. However, they also contribute directly to pathologic vascular thrombosis. This relationship constitutes the rationale for the use of aggressive antiplatelet therapy, including glycoprotein (GP)",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      agents, in the treatment of coronary heart disease (CHD). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Platelet activation can be accomplished via a variety of pharmacologic and mechanical mediators, leading to platelet adhesion and ultimately aggregation. The ability of platelets to adhere to abnormal surfaces and aggregate is mediated by surface membrane glycoprotein (GP) receptors that can be expressed in greater numbers with platelet activation and serve as potential targets for therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'The platelet GP IIb/IIIa receptor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three intravenous GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitors are currently available for clinical use:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"       eptifibatide",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Abciximab'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Tirofiban'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H37\">",
"       'Eptifibatide'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The early trials of these agents were performed before the routine use of dual oral antiplatelet therapy and the use of stent in most patients who undergo percutaneous coronary intervention. These early trials provided substantial evidence of improved outcomes from the use of aggressive antiplatelet therapy in many patients with acute coronary syndromes and some patients undergoing elective stenting. (See",
"      <a class=\"local\" href=\"#H46\">",
"       'Meta-analyses'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The use of these agents in the current era dual oral antiplatelet therapy and PCI with stenting is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H29#H29\">",
"       \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'GP IIb/IIIa inhibitors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H24#H24\">",
"       \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Glycoprotein IIb/IIIa inhibitors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link&amp;anchor=H6#H6\">",
"       \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Timing and dose'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=see_link&amp;anchor=H13#H13\">",
"       \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\", section on 'After half dose fibrinolytic and GP IIb/IIIa inhibitor'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/1\">",
"      Plow EF, Ginsberg MH. Cellular adhesion: GPIIb-IIIa as a prototypic adhesion receptor. Prog Hemost Thromb 1989; 9:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/2\">",
"      Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/3\">",
"      Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994; 343:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/4\">",
"      Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997; 278:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/5\">",
"      Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997; 336:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/6\">",
"      Lincoff AM, Tcheng JE, Califf RM, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation 1999; 99:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/7\">",
"      Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998; 98:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/8\">",
"      Simoons ML, de Boer MJ, van den Brand MJ, et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group. Circulation 1994; 89:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/9\">",
"      Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/10\">",
"      van den Brand M, Laarman GJ, Steg PG, et al. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial. Eur Heart J 1999; 20:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/11\">",
"      Klootwijk P, Meij S, Melkert R, et al. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE). Circulation 1998; 98:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/12\">",
"      Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999; 340:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/13\">",
"      Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/14\">",
"      Bhatt DL, Lincoff AM, Califf RM, et al. The benefit of abciximab in percutaneous coronary revascularization is not device-specific. Am J Cardiol 2000; 85:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/15\">",
"      Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/16\">",
"      Admiral Investigators. Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study. Eur Heart J 2005; 26:2520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/17\">",
"      Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000; 35:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/18\">",
"      Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/19\">",
"      Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003; 42:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/20\">",
"      De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005; 293:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/21\">",
"      EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/22\">",
"      Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999; 341:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/23\">",
"      Kastrati A, Mehilli J, Sch&uuml;hlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/24\">",
"      Simoons ML, GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001; 357:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/25\">",
"      Ottervanger JP, Armstrong P, Barnathan ES, et al. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial. Circulation 2003; 107:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/26\">",
"      Kereiakes DJ, Kleiman NS, Ambrose J, et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996; 27:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/27\">",
"      Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997; 96:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/28\">",
"      Heeschen C, Hamm CW, Goldmann B, et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 1999; 354:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/29\">",
"      Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998; 338:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/30\">",
"      Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol 2004; 44:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/31\">",
"      Cohen M, Gensini GF, Maritz F, et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol 2003; 42:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/32\">",
"      A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998; 338:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/33\">",
"      Lee DP, Herity NA, Hiatt BL, et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation 2003; 107:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/34\">",
"      van 't Hof AW, Ernst N, de Boer MJ, et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 2004; 25:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/35\">",
"      Ernst NM, Suryapranata H, Miedema K, et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004; 44:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/36\">",
"      Van't Hof AW, Ten Berg J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 2008; 372:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/37\">",
"      ten Berg JM, van 't Hof AW, Dill T, et al. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome. J Am Coll Cardiol 2010; 55:2446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/38\">",
"      Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997; 80:11B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/39\">",
"      Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995; 76:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/40\">",
"      Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997; 349:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/41\">",
"      Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998; 339:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/42\">",
"      Kleiman NS, Lincoff AM, Flaker GC, et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation 2000; 101:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/43\">",
"      ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000; 356:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/44\">",
"      Sabatine MS, Jang IK. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Am J Med 2000; 109:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/45\">",
"      Memon MA, Blankenship JC, Wood GC, et al. Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials. Am J Med 2000; 109:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/46\">",
"      Tcheng JE, Kereiakes DJ, Lincoff AM, et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 2001; 104:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/47\">",
"      Madan M, Kereiakes DJ, Hermiller JB, et al. Efficacy of abciximab readministration in coronary intervention. Am J Cardiol 2000; 85:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/48\">",
"      Brown DL, Fann CS, Chang CJ. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention. Am J Cardiol 2001; 87:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/49\">",
"      Batchelor WB, Tolleson TR, Huang Y, et al. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation 2002; 106:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/50\">",
"      Kabbani SS, Aggarwal A, Terrien EF, et al. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 2002; 89:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/51\">",
"      Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/52\">",
"      Roffi M, Moliterno DJ, Meier B, et al. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation 2002; 105:2730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/53\">",
"      Moliterno DJ, Yakubov SJ, DiBattiste PM, et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet 2002; 360:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/54\">",
"      Mukherjee D, Topol EJ, Bertrand ME, et al. Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. Eur Heart J 2005; 26:2524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/55\">",
"      Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103:2572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/56\">",
"      Ohman EM, Kleiman NS, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 1997; 95:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/57\">",
"      Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999; 99:2720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/58\">",
"      de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation 2000; 101:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/59\">",
"      Gibson CM, de Lemos JA, Murphy SA, et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation 2001; 103:2550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/60\">",
"      Antman EM, Gibson CM, de Lemos JA, et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Eur Heart J 2000; 21:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/61\">",
"      Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation 2000; 101:2788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/62\">",
"      Brener SJ, Zeymer U, Adgey AA, et al. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. J Am Coll Cardiol 2002; 39:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/63\">",
"      Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002; 105:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/31/19961/abstract/64\">",
"      Giugliano RP, Roe MT, Harrington RA, et al. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. J Am Coll Cardiol 2003; 41:1251.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1496 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-118.97.94.19-55A78CA94E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_31_19961=[""].join("\n");
var outline_f19_31_19961=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H277514761\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE PLATELET GP IIB/IIIA RECEPTOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ABCIXIMAB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pharmacokinetics and pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ACS patients undergoing PTCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9300137\">",
"      STEMI patients undergoing PCI with stenting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9300316\">",
"      Stable patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9300106\">",
"      Patients not undergoing reperfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      TIROFIBAN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83657274\">",
"      UA/NSTEMI patients undergoing PTCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83657522\">",
"      ACS patients treated medically",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83657537\">",
"      STEMI patients undergoing primary PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83657661\">",
"      Stable patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      EPTIFIBATIDE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Pharmacokinetics and pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      ACS patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Stable patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      META-ANALYSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83657882\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83658977\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83658992\">",
"      Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83659000\">",
"      Allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      COMPARISON OF AGENTS FOR PCI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      COMBINED THERAPY WITH FIBRINOLYTICS AND GP IIb/IIIa ANTAGONISTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H277514761\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1496\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1496|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/27/14783\" title=\"figure 1\">",
"      Platelet adhesion and aggregation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/37/607\" title=\"figure 2\">",
"      Abciximab in stenting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/3/38973\" title=\"figure 3\">",
"      Six month outcome EPISTENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/32/14862\" title=\"figure 4\">",
"      Tirofiban elevated troponin I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/52/28493\" title=\"figure 5\">",
"      Tirofiban unstable angina PRISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1496|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/19/38203\" title=\"table 1\">",
"      Agonists for platelet activation and their receptors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=related_link\">",
"      Antithrombotic therapy for intracoronary stent implantation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=related_link\">",
"      Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=related_link\">",
"      Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40089?source=related_link\">",
"      Periprocedural bleeding in patients undergoing percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7318?source=related_link\">",
"      Structure of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4167?source=related_link\">",
"      The role of platelets in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/21/24918?source=related_link\">",
"      Thrombocytopenia induced by glycoprotein IIb/IIIa inhibitors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_31_19962="Morphine sulfate: Drug information";
var content_f19_31_19962=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Morphine sulfate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/33/14870?source=see_link\">",
"    see \"Morphine sulfate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=see_link\">",
"    see \"Morphine sulfate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8775511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8776636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Astramorph/PF&trade;;",
"     </li>",
"     <li>",
"      AVINza&reg;;",
"     </li>",
"     <li>",
"      Duramorph;",
"     </li>",
"     <li>",
"      Infumorph 200;",
"     </li>",
"     <li>",
"      Infumorph 500;",
"     </li>",
"     <li>",
"      Kadian&reg;;",
"     </li>",
"     <li>",
"      MS Contin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8776637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Doloral;",
"     </li>",
"     <li>",
"      Kadian&reg;;",
"     </li>",
"     <li>",
"      M-Eslon&reg;;",
"     </li>",
"     <li>",
"      M.O.S.-SR&reg;;",
"     </li>",
"     <li>",
"      M.O.S.-Sulfate&reg;;",
"     </li>",
"     <li>",
"      M.O.S.&reg; 10;",
"     </li>",
"     <li>",
"      M.O.S.&reg; 20;",
"     </li>",
"     <li>",
"      M.O.S.&reg; 30;",
"     </li>",
"     <li>",
"      Morphine Extra Forte Injection;",
"     </li>",
"     <li>",
"      Morphine Forte Injection;",
"     </li>",
"     <li>",
"      Morphine HP&reg;;",
"     </li>",
"     <li>",
"      Morphine LP&reg; Epidural;",
"     </li>",
"     <li>",
"      Morphine SR;",
"     </li>",
"     <li>",
"      Morphine-EPD;",
"     </li>",
"     <li>",
"      MS Contin SRT;",
"     </li>",
"     <li>",
"      MS Contin&reg;;",
"     </li>",
"     <li>",
"      MS-IR&reg;;",
"     </li>",
"     <li>",
"      Novo-Morphine SR;",
"     </li>",
"     <li>",
"      PMS-Morphine Sulfate SR;",
"     </li>",
"     <li>",
"      ratio-Morphine;",
"     </li>",
"     <li>",
"      ratio-Morphine SR;",
"     </li>",
"     <li>",
"      Sandoz-Morphine SR;",
"     </li>",
"     <li>",
"      Statex&reg;;",
"     </li>",
"     <li>",
"      Teva-Morphine SR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8776648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Opioid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8776811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     These are guidelines and do not represent the doses that may be required in all patients. Doses and dosage intervals should be titrated to pain relief/prevention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Acute pain (moderate-to-severe):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral (immediate release formulations):",
"     </i>",
"     Opioid-naive: Initial:",
"     <b>",
"      Note:",
"     </b>",
"     Usual dosage range: 10-30 mg every 4 hours as needed. Patients with prior opioid exposure may require higher initial doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Solution: 10-20 mg every 4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet: 15-30 mg every 4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., SubQ:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Repeated SubQ administration causes local tissue irritation, pain, and induration. The use of I.M. injections is no longer recommended especially for repeated administration due to painful administration, variable absorption and lag time to peak effect; other routes are more reliable and less painful (APS, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: Opioid-naive: 5-10 mg every 4 hours as needed; usual dosage range: 5-15 mg every 4 hours as needed. Patients with prior opioid exposure may require higher initial doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     Initial: Opioid-naive: 2.5-5 mg every 3-4 hours; patients with prior opioid exposure may require higher initial doses.",
"     <b>",
"      Note:",
"     </b>",
"     Administration of 2-3 mg every 5 minutes until pain relief or if associated sedation, oxygen saturation &lt;95%, or serious adverse event occurs may be appropriate in treating acute moderate-to-severe pain in settings such as the immediate postoperative period or the emergency department (Aubrun, 2012; Lvovschi, 2008); dose reduction in the immediate postoperative period (postanesthesia care unit) in the elderly is usually not necessary (Aubrun, 2002).  A maximum cumulative dose (eg, 10 mg) prompting reevaluation of continued morphine use and/or dose should be included as part of any medication order intended for short-term use (eg, PACU orders). Refer to institution-specific protocols as appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Acute myocardial infarction, analgesia (unlabeled use): Initial management: 4-8 mg (lower doses in the elderly); subsequently may give 2-8 mg every 5-15 minutes as needed (O'Gara, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Critically-ill patients, analgesia (unlabeled dose): 2-4 mg every 1-2 hours",
"     <b>",
"      or",
"     </b>",
"     4-8 mg every 3-4 hours as needed (Barr, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V., SubQ continuous infusion:",
"     </i>",
"     0.8-10 mg/hour; usual range: Up to 80 mg/hour.",
"     <b>",
"      Note:",
"     </b>",
"     May administer a loading dose (amount administered should depend on severity of pain) prior to initiating the infusion. A continuous (basal) infusion is not  recommended in an opioid-naive patient (ISMP, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous infusion for critically-ill patients: Usual dosage range: 2-30 mg/hour (Barr, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patient-controlled analgesia (PCA) (APS, 2008):",
"     <b>",
"      Note:",
"     </b>",
"     In opioid-naive patients, consider lower end of dosing range:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Usual concentration: 1 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Demand dose: Usual: 1 mg; range: 0.5-2.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Lockout interval: 5-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Epidural:",
"     </i>",
"     Pain management:",
"     <b>",
"      Note: Must be preservative-free.",
"     </b>",
"     Administer with extreme caution and in reduced dosage to geriatric or debilitated patients. Vigilant monitoring is particularly important in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Single-dose:",
"     <b>",
"      Lumbar region:",
"     </b>",
"     Astramorph/PF&trade;, Duramorph: 30-100 mcg/kg (optimal range: 2.5-3.75 mg; may depend upon patient comorbidities; Bujedo, 2012; Sultan, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Continuous infusion (may be combined with bupivacaine): 0.2-0.4 mg/hour (Bujedo, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous microinfusion (Infumorph):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Opioid-naive: Initial: 3.5-7.5 mg over 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Opioid-tolerant: Initial: 4.5-10 mg over 24 hours, titrate to effect; usual maximum is ~30 mg per 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intrathecal (I.T.):",
"     </i>",
"     <b>",
"      Note: Must be preservative-free.",
"     </b>",
"     Administer with extreme caution and in reduced dosage to geriatric or debilitated patients. I.T. dose is usually",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      10",
"     </sub>",
"     (one-tenth) that of epidural dosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Opioid-naive: Single dose: Lumbar region: Astramorph/PF&trade;, Duramorph: 0.1-0.3 mg (may provide adequate relief for up to 24 hours; APS, 2008); repeat doses are",
"     <b>",
"      not",
"     </b>",
"     recommended. If pain recurs within 24 hours of administration, use of an alternate route of administration is recommended.",
"     <b>",
"      Note:",
"     </b>",
"     Although product labeling recommends doses up to 1 mg, an analgesic ceiling exists with doses &gt;0.3 mg and the risk of respiratory depression is higher with doses &gt;0.3 mg (Rathmell, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Continuous microinfusion (Infumorph): Lumbar region: After initial in-hospital evaluation of response to single-dose injections (Astramorph/PF&trade;, Duramorph) the initial dose of Infumorph is 0.2-1 mg over 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Opioid-tolerant: Continuous microinfusion (Infumorph): Lumbar region: Dosage range: 1-10 mg over 24 hours, titrate to effect; usual maximum is ~20 mg over 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Rectal:",
"     </i>",
"     10-20 mg every 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Chronic pain:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Patients taking opioids chronically may become tolerant and require doses higher than the usual dosage range to maintain the desired effect. Tolerance can be managed by appropriate dose titration. There is no optimal or maximal dose for morphine in chronic pain. The appropriate dose is one that relieves pain throughout its dosing interval without causing unmanageable side effects. Consider total daily dose, potency, prior opioid use, degree of opioid experience and tolerance, conversion from previous opioid (including opioid formulation), patient&rsquo;s general condition, concurrent medications, and type and severity of pain during prescribing process.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral (extended release formulations):",
"     </i>",
"     A patient's morphine requirement should be established using immediate release formulations. Conversion to long-acting products may be considered when chronic, continuous treatment is required. Higher dosages should be reserved for use only in opioid-tolerant patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Capsules, extended release (Avinza&reg;): Daily dose administered once daily (for best results, administer at same time each day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Opioid-naive: Initial: 30 mg once daily; adjust in increments &le;30 mg daily every 4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Conversion from other oral morphine formulations to Avinza&reg;:  Total daily morphine dose given as once daily.  The first dose of Avinza&reg; may be taken with the last dose of the immediate release morphine. Maximum: 1600 mg daily due to fumaric acid content.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Capsules, extended release (Kadian&reg;):",
"     <b>",
"      Note:",
"     </b>",
"     Not intended for use as an initial opioid in the management of pain; use immediate release formulations before initiation. Total daily oral morphine dose may be either administered once daily or in 2 divided doses daily (every 12 hours). The first dose of Kadian&reg; may be taken with the last dose of the immediate release morphine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablets, extended  release (MS Contin&reg;): Daily dose divided and administered every 8 or every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Conversion from parenteral morphine or other opioids to extended release formulations: Substantial interpatient variability exists in relative potency. Therefore, it is safer to underestimate a patient&rsquo;s daily oral morphine requirement and provide breakthrough pain relief with immediate release morphine than to overestimate requirements. Consider the parenteral to oral morphine ratio or other oral or parenteral opioids to oral morphine conversions.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8776810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=see_link\">",
"      see \"Morphine sulfate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     These are guidelines and do not represent the doses that may be required in all patients. Doses and dosage intervals should be titrated to pain relief/prevention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Acute pain (moderate-to-severe):",
"     </b>",
"     Children &gt;6 months and &lt;50 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral (immediate release formulations):",
"     </i>",
"     0.15-0.3 mg/kg every 3-4 hours as needed.",
"     <b>",
"      Note:",
"     </b>",
"     The American Pain Society recommends an initial dose of 0.3 mg/kg for children with severe pain (American Pain Society [APS], 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., SubQ:",
"     </i>",
"     0.1-0.2 mg/kg;",
"     <b>",
"      Note:",
"     </b>",
"     Repeated SubQ administration causes local tissue irritation, pain, and induration. The use of I.M. injections is no longer recommended especially for repeated administration due to painful administration, variable absorption and lag time to peak effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     0.05-0.3 mg/kg every 3-4 hours as needed, not to exceed 10 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Continuous infusion:",
"     </i>",
"     Initial: 10-30",
"     <b>",
"      mcg/kg/hour",
"     </b>",
"     ; titrate as needed to control pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patient-controlled analgesia (PCA)",
"     </i>",
"     (APS, 2008):",
"     <b>",
"      Note:",
"     </b>",
"     Opioid-naive: Consider lower end of dosing range:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Usual concentration: 1 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Demand dose: Usual: 0.02 mg/kg/dose; range: 0.01-0.03 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lockout interval: 8-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Usual basal rate: 0-0.03 mg/kg/hour",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8776812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use with caution; may require reduced dosage in the elderly and debilitated patients.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8776813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Children and Adults: Administer at 75% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Children and Adults: Administer at 50% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intermittent HD:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Administer 50% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Children: Administer 50% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     CRRT: Children and Adults: Administer 75% of normal dose, titrate.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8776814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling. Pharmacokinetics unchanged in mild liver disease; substantial extrahepatic metabolism may occur. In cirrhosis, increases in half-life and AUC suggest dosage adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8776907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as sulfate: 10 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg, 100 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kadian&reg;: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 100 mg, 130 mg, 150 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as sulfate [bi-modal release]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AVINza&reg;: 30 mg, 45 mg, 60 mg, 75 mg, 90 mg, 120 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate: 1 mg/mL (10 mL); 2 mg/mL (1 mL); 4 mg/mL (1 mL); 5 mg/mL (1 mL); 8 mg/mL (1 mL); 10 mg/mL (1 mL, 10 mL); 10 mg/0.7 mL (0.7 mL); 15 mg/mL (1 mL, 20 mL); 25 mg/mL (4 mL, 10 mL); 50 mg/mL (20 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate [preservative free]: 0.5 mg/mL (10 mL); 1 mg/mL (10 mL); 25 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate [epidural or intrathecal infusion via microinfusion device, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infumorph 200: 10 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infumorph 500: 25 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate [epidural, intrathecal, or I.V. infusion, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Astramorph/PF&trade;: 0.5 mg/mL (2 mL, 10 mL); 1 mg/mL (2 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duramorph: 0.5 mg/mL (10 mL); 1 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate [for PCA pump]: 1 mg/mL (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate [for PCA pump, preservative free]: 1 mg/mL (30 mL); 5 mg/mL (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as sulfate: 10 mg/5 mL (5 mL, 100 mL, 500 mL); 20 mg/5 mL (100 mL, 500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as sulfate [concentrate]: 100 mg/5 mL (15 mL, 30 mL, 120 mL, 240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal, as sulfate: 5 mg (12s); 10 mg (12s); 20 mg (12s); 30 mg (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sulfate: 15 mg, 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as sulfate: 15 mg, 30 mg, 60 mg, 100 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MS Contin&reg;: 15 mg, 30 mg, 60 mg, 100 mg, 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F8776908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Doloral: 1 mg/mL (10 mL, 250 mL, 500 mL); 5 mg/mL (10 mL, 250 mL, 500 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8776646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes Avinza&reg; extended release capsule",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F8776634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9845085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     AVINza&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM311346.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM311346.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Kadian&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM311373.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM311373.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     MS Contin&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM311374.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM311374.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Oral solution:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM199333.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM199333.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8776887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Do not crush, chew, or dissolve extended release drug product; swallow whole. Kadian&reg; and Avinza&reg; can be opened and sprinkled on applesauce and eaten immediately without chewing; do not crush, dissolve, or chew the beads as it can result in a rapid release of a potentially fatal dose of morphine. Ensure all pellets have been swallowed by rinsing mouth. Contents of Kadian&reg; capsules may be opened and sprinkled over 10 mL water and flushed through prewetted 16F gastrostomy tube; do not administer Kadian&reg; through gastric/nasogastric tubes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: When giving morphine I.V. push, it is best to first dilute with sterile water or NS for a final concentration of 1-2 mg/mL and then administer slowly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Epidural, intrathecal: Use preservative-free solutions for intrathecal or epidural use. Infumorph may",
"     <b>",
"      only",
"     </b>",
"     be used as a continuous microinfusion via catheter.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14472937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     0.1 mg/mL, 0.5 mg/mL,",
"     <b>",
"      or",
"     </b>",
"     1 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8776767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, aldesleukin, allopurinol, amifostine, amikacin, aminophylline, amiodarone, ampicillin, ampicillin/sulbactam, amsacrine, anidulafungin, argatroban, atenolol, atracurium, atropine, aztreonam, bivalirudin, bumetanide, caffeine citrate, calcium chloride, caspofungin, cefazolin, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftizoxime, cefuroxime, chloramphenicol, cisatracurium, cisplatin, cladribine, clindamycin, cyclophosphamide, cytarabine, dexamethasone sodium phosphate, dexmedetomidine, diazepam, digoxin, diltiazem, diphenhydramine, dobutamine, docetaxel, dopamine, doripenem, doxorubicin, doxycycline, enalaprilat, epinephrine, eptifibatide, erythromycin lactobionate, esmolol, etomidate, etoposide phosphate, famotidine, fenoldopam, fentanyl, filgrastim, fluconazole, fludarabine, foscarnet, gemcitabine, gentamicin, granisetron, haloperidol, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, hydroxyzine, IL-2, insulin (regular), kanamycin, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, lorazepam, magnesium sulfate, melphalan, meropenem, methotrexate, methotrimeprazine, methyldopate, methylprednisolone sodium succinate, metoclopramide, metoprolol, metronidazole, midazolam, milrinone, nafcillin, nicardipine, nitroglycerin, nitroprusside, norepinephrine, ondansetron, oxacillin, oxaliplatin, oxytocin, paclitaxel, palonosetron, pancuronium, pemetrexed, penicillin G potassium, phenobarbital, piperacillin, piperacillin/tazobactam, potassium chloride, propranolol, ranitidine, remifentanil, scopolamine, sodium bicarbonate, tacrolimus, teniposide, thiotepa, ticarcillin/clavulanate, tigecycline, tirofiban, tobramycin, trimethoprim/sulfamethoxazole, vancomycin, vecuronium, vinorelbine, vitamin B complex with C, warfarin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Alteplase, alatrofloxacin, amphotericin B cholesteryl sulfate complex, azithromycin, doxorubicin liposome, gallium nitrate, lansoprazole, micafungin, minocycline, phenytoin, sargramostim.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Acyclovir, cefepime, ceftriaxone, furosemide, nesiritide, pantoprazole, propofol, thiopental.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Alfentanil, atropine, bupivacaine, bupivacaine with clonidine, butorphanol, caffeine citrate, cimetidine, clonidine, dimenhydrinate, diphenhydramine, droperidol, fentanyl, glycopyrrolate, hydroxyzine, ketamine with lidocaine, lidocaine, metoclopramide, midazolam, milrinone, ondansetron, pentazocine, ranitidine, rocuronium, scopolamine, ziconotide.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Haloperidol, meperidine, pantoprazole, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Chlorpromazine, heparin, ketamine, octreotide,  pentobarbital, prochlorperazine edisylate, promethazine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8776698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of moderate-to-severe acute and chronic pain; relief of pain of myocardial infarction; relief of dyspnea of acute left ventricular failure and pulmonary edema; preanesthetic medication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infumorph: Used in continuous microinfusion devices for intrathecal or epidural administration in treatment of intractable chronic pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release products: Moderate-to-severe pain when continuous, around-the-clock opioid analgesia is needed for an extended period of time",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note: Opioid tolerance:",
"     </b>",
"     Use of morphine sulfate extended release tablets/capsules &ge;90 mg, and/or the oral solution 100 mg/5 mL (20 mg/mL) should be reserved for opioid-tolerant patients (ie, already taking at least 60 mg daily of oral morphine equivalent for at least 1 week).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8775520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Morphine may be confused with HYDROmorphone, methadone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Morphine sulfate may be confused with magnesium sulfate",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Kadian&reg; may be confused with Kapidex [DSC]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       MS Contin&reg; may be confused with OxyCONTIN&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       MSO",
"       <sub>",
"        4",
"       </sub>",
"       and MS are error-prone abbreviations (mistaken as magnesium sulfate)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       AVINza&reg; may be confused with Evista&reg;, INVanz&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Roxanol may be confused with OxyFast&reg;, Roxicet&trade;, Roxicodone&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Use care when prescribing and/or administering morphine solutions. These products are available in different concentrations. Always prescribe dosage in mg;",
"       <b>",
"        not",
"       </b>",
"       by volume (mL).",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Use caution when selecting a morphine formulation for use in neurologic infusion pumps (eg, Medtronic delivery systems). The product should be appropriately labeled as &ldquo;preservative-free&rdquo; and suitable for intraspinal use via continuous infusion. In addition, the product should be formulated in a pH range that is compatible with the device operation specifications.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Significant differences exist between oral and I.V. dosing. Use caution when converting from one route of administration to another.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8776723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Individual patient differences are unpredictable, and percentage may differ in acute pain (surgical) treatment. Reactions may be dose, formulation, and/or route dependent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Circulatory depression, flushing, shock",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Dysphonia, physical and psychological dependence, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Antidiuretic hormone release, hypogonadism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone mineral density decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness (9% to 48%; tolerance usually develops to drowsiness with regular dosing for 1-2 weeks), dizziness (6% to 20%), fever (&lt;3% to &gt;10%), confusion, headache (following epidural or intrathecal use)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (may be dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (78%), constipation (9% to 40%; tolerance develops very slowly if at all), nausea (7% to 28%; tolerance usually develops to nausea and vomiting with chronic use), vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary retention (16%; may be prolonged, up to 20 hours, following epidural or intrathecal use)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (following intrathecal use)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Pain at injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Oxygen saturation decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Histamine release",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Atrial fibrillation (&lt;3%), chest pain (&lt;3%), edema, hypertension, palpitation, peripheral edema, syncope, tachycardia, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Amnesia, agitation, anxiety, apathy, apprehension, ataxia, chills, coma, delirium, depression, dream abnormalities, euphoria, false sense of well being, hallucination, hypoesthesia, insomnia, lethargy, malaise, nervousness, restlessness, seizure, slurred speech, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dry skin, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gynecomastia (&lt;3%), hypokalemia, hyponatremia, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distension, abdominal pain, anorexia, biliary colic, diarrhea, dyspepsia, dysphagia, flatulence, gastroenteritis, GERD, GI irritation, paralytic ileus, rectal disorder, taste perversion, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Bladder spasm, dysuria, ejaculation abnormal, impotence, urination decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (&lt;3%), thrombocytopenia (&lt;3%), hematocrit decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver function tests increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, bone pain, foot drop, gait abnormalities, paresthesia, rigors, skeletal muscle rigidity, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Amblyopia, conjunctivitis, eye pain, vision problems/disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Oliguria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Asthma, atelectasis, dyspnea, hiccups, hypercapnia, hypoxia, pulmonary edema (noncardiogenic), respiratory depression, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, flu-like syndrome, infection, thirst, voice alteration, withdrawal syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Amenorrhea, anaphylaxis, apnea, biliary tract spasm, blurred vision, bronchospasm, cardiac arrest, cough reflex decreased, dehydration, diplopia, disorientation, hemorrhagic urticaria, intestinal obstruction, intracranial pressure increased, laryngospasm, menstrual irregularities, miosis, myoclonus, nystagmus, paradoxical CNS stimulation, respiratory arrest, sepsis, urinary tract spasm, thermal dysregulation, toxic psychoses",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8776704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Some contraindications are product specific. For details, please see detailed product prescribing information.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hypersensitivity to morphine sulfate or any component of the formulation; severe respiratory depression, acute or severe asthma (in an unmonitored setting or without resuscitative equipment); known or suspected paralytic ileus",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Additional contraindication information (based on formulation):",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"     Epidural/intrathecal:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;margin-top:0em;\">",
"     Astramorph/PF&trade;, Duramorph: Upper airway obstruction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Astramorph/PF&trade;, Duramorph, Infumorph: Usual contraindications related to neuraxial analgesia apply (eg, presence of infection at infusion site, concomitant anticoagulant therapy, uncontrolled bleeding diathesis)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"     Extended release: GI obstruction",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"     Immediate release tablets/solution: Hypercarbia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Injectable formulation: Heart failure due to chronic lung disease, cardiac arrhythmias; increased intracranial pressure, head injuries, brain tumors;  acute alcoholism, deliriums tremens; seizure disorders; use during labor when a premature birth is anticipated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Suppository: Severe CNS depression; cardiac arrhythmias, heart failure due to chronic lung disease; increased intracranial or cerebrospinal pressure, head injuries, brain tumor; acute alcoholism, delirium tremens; seizure disorder; use after biliary tract surgery, suspected surgical abdomen, surgical anastomosis;  concurrent use or within 2 weeks of MAO inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8776705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension; use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), circulatory shock, or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics). May cause orthostatic hypotension and syncope in ambulatory patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (codeine, hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory depression: All morphine sulfate formulations are capable of causing respiratory depression; risk increased in elderly patients, debilitated patients, and patients with conditions associated with hypoxia or hypercapnia. Monitor for respiratory depression especially during initiation and titration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;text-align:justify;\">",
"     -",
"     <i>",
"      Extended release formulations:",
"     </i>",
"     <b>",
"      [U.S. Boxed Warning]: Fatal respiratory depression has occurred with administration with the highest risk at initiation and with dosage increases. Proper dosing and titration should be done by a healthcare professional who is knowledgeable in the use of potent opioids for chronic pain management. Instruct patient about proper administration to prevent rapid release and absorption of long-acting products. Crushing, dissolving, or chewing of the long acting products can cause the delivery of  a potentially fatal dose of morphine.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions. May worsen gastrointestinal ileus due to reduced GI motility. Contraindicated in patients with paralytic ileus; avoid use in patients with GI obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse/misuse/diversion: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance and psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;text-align:justify;\">",
"     -",
"     <i>",
"      Extended release formulations:",
"     </i>",
"     <b>",
"      [U.S. Boxed Warning]: Healthcare provider should be alert to problems of abuse, misuse, addiction, and diversion.",
"     </b>",
"     Assess patient&rsquo;s abuse potential based upon personal or family history of substance abuse or addiction (drug or ethanol) or mental illness (eg, major depressive disorder)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction including acute pancreatitis. Use may cause constriction of sphincter of Oddi diminishing biliary and pancreatic secretions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression/coma: Use with caution in patients with CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intracranial pressure (ICP): Use with extreme caution in patients with head injury, intracranial lesions, or elevated ICP; exaggerated elevation of ICP may occur if respiratory drive is depressed and CO",
"     <sub>",
"      2",
"     </sub>",
"     retention occurs. Some dosage forms are contraindicated with increased ICP or head trauma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Use with caution in patients who are morbidly obese.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, decreased respiratory reserve, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages. Consider alternative nonopioid analgesics in this patient population if possible. Some dosage forms may be contraindicated in patients with severe respiratory disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with seizure disorders; may cause or exacerbate pre-existing seizures. Some dosage forms may be contraindicated in patients with seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs, CNS depressants, antihistamines, or psychotropic drugs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cachectic or debilitated patients: Use with caution in cachectic or debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose. Use epidural/intrathecal formulations (Astramorph/PF&trade;, Duramorph, Infumorph) with extreme caution in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Infants &lt;3 months  of age, especially if premature, are more susceptible to respiratory depression and/or apnea; use with caution and generally in reduced doses in this age group.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate administration: Astramorph/PF&trade;, Duramorph, Infumorph:",
"     <b>",
"      [U.S. Boxed Warning]: Due to the risk of severe and/or sustained cardiopulmonary depressant effects of Astramorph/PF&trade;, Duramorph, and Infumorph, they must be administered in a fully equipped (ie, for resuscitation) and staffed environment.",
"     </b>",
"     Naloxone injection should be immediately available. Patient should remain in this environment for at least 24 hours following the initial dose. For patients receiving Infumorph via microinfusion device, patient may be observed, as appropriate, for the first several days after catheter implantation.  Thoracic epidural administration has been shown to dramatically increase the risk of early and late respiratory depression.",
"     <b>",
"      [U.S. Boxed Warning]: Accidental dermal exposure to Astramorph/PF&trade;, Duramorph, Infumorph should be rinsed with water. Contaminated clothing should be removed.",
"     </b>",
"     Prior to administration, inspect parenteral products for particulate matter and discoloration if possible. Do not use if color is darker than pale yellow or if discolored.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Avinza&reg;:",
"     <b>",
"      [U.S. Boxed Warning]: Do not administer Avinza&reg; with alcoholic beverages or ethanol-containing products, which may disrupt extended-release characteristic of product.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extended release formulations:",
"     <b>",
"      [U.S. Boxed Warning]: Should not be crushed, dissolved, or chewed as can cause rapid release and absorption of a potentially fatal dose of morphine.",
"     </b>",
"     Not to be used on an as needed basis; not for mild acute pain that is not expected to persist for an extended period of time, acute pain, or postoperative pain unless the patient is already receiving chronic opioid therapy or if postoperative pain is expected to be moderate to severe and persistent for an extended period of time.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;text-align:justify;\">",
"     -",
"     <i>",
"      Avinza&reg; capsules:",
"     </i>",
"     Dosage form contains fumaric acid; dangerous quantities of fumaric acid may be ingested when &gt;1600 mg/day is used. Serious renal toxicity may occur above the maximum dose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;text-align:justify;\">",
"     -",
"     <i>",
"      Extended release formulations:",
"     </i>",
"     Extended release products are not interchangeable. When determining a generic equivalent or switching from one extended release product to another, a thorough understanding of the pharmacokinetic properties is important in determining the proper generic equivalent or proper dose of the other extended release product (review of the manufacturer&rsquo;s label may be necessary).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Highly concentrated oral solutions:",
"     <b>",
"      [U.S. Boxed Warning]: Check doses carefully when using highly concentrated oral solutions. The 100 mg/5 mL (20 mg/mL) concentration is indicated for use in opioid-tolerant patients only.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injections: Products are designed for administration by specific routes (ie, I.V., intrathecal, epidural). Use caution when prescribing, dispensing, or administering to use formulations only by intended route(s).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product interchange: Infumorph solutions:",
"     <b>",
"      [U.S. Boxed Warning]: Improper or erroneous substitution of Infumorph for regular Duramorph is likely to result in serious overdosage, leading to seizures, respiratory depression and possibly a fatal outcome. Infumorph should only be used in microinfusion devices;",
"     </b>",
"     not for I.V., I.M., or SubQ administration or for single-dose administration. Monitor closely, especially in the first 24 hours. Inflammatory masses (eg, granulomas), some resulting in severe neurologic impairment have occurred when receiving Infumorph via indwelling intrathecal catheter; monitor carefully for new neurologic signs/symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfites: Some intravenous preparations contain sulfites which may cause allergic reactions in sulfite sensitive patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epidural use: Astramorph/PF&trade;, Duramorph, Infumorph: When used as an epidural injection, monitor for delayed sedation and respiratory depression. Physician should evaluate patient for contraindications for epidural injection (eg, anticoagulant therapy, bleeding, diathesis, etc).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intrathecal: Astramorph/PF&trade;, Duramorph, Infumorph:",
"     <b>",
"      [U.S. Boxed Warning]: Intrathecal dosage is usually",
"      <sup>",
"       1",
"      </sup>",
"      /",
"      <sub>",
"       10",
"      </sub>",
"      (one-tenth) that of epidural dosage.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Optimal regimen: An opioid-containing analgesic regimen should be tailored to each patient's needs and based upon the type of pain being treated (acute versus chronic), the route of administration, degree of tolerance for opioids (naive versus chronic user), age, weight, and medical condition. The optimal analgesic dose varies widely among patients; doses should be titrated to pain relief/prevention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Overdose: Extended release formulations, concentrated oral solution (100 mg/5 mL):",
"     <b>",
"      [U.S. Boxed Warning]: Fatal overdose of morphine can result from accidental ingestion, especially in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms. Gradually reduce dose over a short period of time.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8776734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8776735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Morphine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8776739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Alcoholic beverages or ethanol-containing products may disrupt extended release formulation resulting in rapid release of entire morphine dose. Ethanol may also increase CNS depression. Management: Avoid alcohol.",
"     <b>",
"      Do not administer Avinza&reg; with alcoholic beverages or ethanol-containing prescription or nonprescription products.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Administration of oral morphine solution with food may increase bioavailability (ie, a report of 34% increase in morphine AUC when morphine oral solution followed a high-fat meal). The bioavailability of Avinza&reg;, MS Contin&reg;, or Kadian&reg; does not appear to be affected by food. Management: Take consistently with or without meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Gotu kola, valerian, and kava kava may increase CNS depression. Management: Avoid gotu kola, valerian, and kava kava.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8776699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8776700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies; however reduced growth and behavioral abnormalities in offspring have been observed. Morphine crosses the human placenta. The frequency of congenital malformations has not been reported to be greater than expected in children from mothers treated with morphine during pregnancy. However, following",
"     <i>",
"      in utero",
"     </i>",
"     exposure, infants may exhibit withdrawal, decreased brain volume (reversible), small size, decreased ventilatory response to CO",
"     <sub>",
"      2",
"     </sub>",
"     , and increased risk of sudden infant death syndrome. In patients with chronic, noncancer pain, minimal (if any) opioids should be used during pregnancy. Neonates born to mothers receiving chronic opioids during pregnancy should be monitored for neonatal withdrawal syndrome.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8776702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8776703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Morphine concentrates in breast milk, with a milk to plasma AUC ratio of 2.5:1. Detectable serum levels of morphine can be found in infants following morphine administration to nursing mothers. Treatment of the mother with single doses of morphine is not expected to cause detrimental effects in nursing infants. Breast-feeding following chronic use or in neonates with hepatic or renal dysfunction may lead to higher levels of morphine in the infant and a risk of adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8776886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Morphine may cause GI upset; take with food if GI upset occurs. Be consistent when taking morphine with or without meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8776910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (AVINza Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $577.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45 mg (100): $856.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $1121.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $1426.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg (100): $1685.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (100): $1989.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Kadian Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $552.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $610.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $663.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $884.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $1108.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $1326.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     70 mg (100): $1548.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (100): $1767.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $2217.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     130 mg (100): $2882.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $3326.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $4435.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Morphine Sulfate ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $522.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $568.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $1136.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (100): $1513.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $1898.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Device",
"     </b>",
"     (Morphine Sulfate Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/0.7 mL (0.7 mL): $26.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Astramorph Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg/mL (2 mL): $9.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (2 mL): $10.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Infumorph 200 Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 MG/20ML (10 mg/mL) (20 mL): $156.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Infumorph 500 Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 MG/20ML (25 mg/mL) (20 mL): $264.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Morphine Sulfate (Concentrate) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (30 mL): $25.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Morphine Sulfate (PF) Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (10 mL): $3.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Morphine Sulfate (PF) Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/mL (1 mL): $1.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg/mL (1 mL): $1.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (1 mL): $1.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/mL (1 mL): $1.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Morphine Sulfate in Dextrose Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL 5% (100 mL): $10.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Morphine Sulfate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (1 mL): $1.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/mL (1 mL): $1.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/mL (1 mL): $1.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg/mL (1 mL): $1.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (1 mL): $1.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/mL (1 mL): $1.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Morphine Sulfate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (10 mL): $7.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/mL (10 mL): $11.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (20 mL): $11.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Morphine Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/5 mL (100 mL): $12.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/5 mL (100 mL): $17.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Morphine Sulfate Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (12): $60.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (12): $75.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (12): $90.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (12): $112.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Morphine Sulfate ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $89.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $169.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $331.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $490.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $898.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (MS Contin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $212.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $404.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $789.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $1168.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $2139.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Morphine Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $22.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $37.77",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8776892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Assess efficacy of pain control, vital signs, and mental status; signs of drug abuse, addiction, or diversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Astramorph/PF&trade;, Duramorph, Infumorph: Patients should be observed in a fully-equipped and staffed environment for at least 24 hours following initiation, and as appropriate for the first several days after catheter implantation. Naloxone injection should be immediately available. Patient should remain in this environment for at least 24 hours following the initial dose. For patients receiving Infumorph via microinfusion device, patient may be observed, as appropriate, for the first several days after catheter implantation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Also refer to institution specific protocols as appropriate.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anamorph (AU);",
"     </li>",
"     <li>",
"      Contalgin (DK);",
"     </li>",
"     <li>",
"      Depolan (FI);",
"     </li>",
"     <li>",
"      Dimorf (BR);",
"     </li>",
"     <li>",
"      Dimorf SP (PY);",
"     </li>",
"     <li>",
"      Dolcontin (FI, SE);",
"     </li>",
"     <li>",
"      Dolcontin Depottab (NO);",
"     </li>",
"     <li>",
"      Doltard (DK, EE);",
"     </li>",
"     <li>",
"      Kapanol (AU);",
"     </li>",
"     <li>",
"      La Morph (NZ);",
"     </li>",
"     <li>",
"      M-Eslon (CN, CO, EC, PE);",
"     </li>",
"     <li>",
"      M.I.R. (IL);",
"     </li>",
"     <li>",
"      MCR (IL);",
"     </li>",
"     <li>",
"      Morficontin (GR);",
"     </li>",
"     <li>",
"      Morphanton (DE);",
"     </li>",
"     <li>",
"      Morphgesic SR (GB);",
"     </li>",
"     <li>",
"      Moscontin (FR);",
"     </li>",
"     <li>",
"      MS Contin (AU, BE, CL, IT, NL, VE);",
"     </li>",
"     <li>",
"      MS Contin CR (KP);",
"     </li>",
"     <li>",
"      MS Mono (AU);",
"     </li>",
"     <li>",
"      MSP (IL);",
"     </li>",
"     <li>",
"      MST (PT);",
"     </li>",
"     <li>",
"      MST Continus (AE, AR, BF, BG, BH, BJ, CI, CY, CZ, EE, EG, ET, GB, GH, GM, GN, HK, HN, ID, IE, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, OM, PH, PK, PL, QA, SA, SC, SD, SG, SL, SN, SY, TH, TN, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      MST Continus Retard (CH);",
"     </li>",
"     <li>",
"      Mundidol Retard (AT);",
"     </li>",
"     <li>",
"      MXL (TW);",
"     </li>",
"     <li>",
"      Oramorph (BE, FR, GB, IE, PT, SE);",
"     </li>",
"     <li>",
"      RA-Morph (NZ);",
"     </li>",
"     <li>",
"      Rumorf (IN);",
"     </li>",
"     <li>",
"      S-Morphine (KP);",
"     </li>",
"     <li>",
"      Sevredol (AU, CH, CZ, NZ);",
"     </li>",
"     <li>",
"      Statex (SG);",
"     </li>",
"     <li>",
"      Vendal (UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8776768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to opioid receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8776772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action (patient dependent; dosing must be individualized): Oral (immediate release): ~30 minutes; I.V.: 5-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration (patient dependent; dosing must be individualized): Pain relief:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release formulations: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release capsule and tablet: 8-24 hours (formulation dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Variable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1-6 L/kg; binds to opioid receptors in the CNS and periphery (eg, GI tract)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 20% to 35%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via conjugation with glucuronic acid primarily to morphine-6-glucuronide (active analgesic) morphine-3-glucuronide (inactive as analgesic); minor metabolites include morphine-3-6-diglucuronide; other minor metabolites include normorphine (active) and morphine 3-ethereal sulfate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 17% to 33% (first-pass effect limits oral bioavailability; oral:parenteral effectiveness reportedly varies from 1:6 in opioid naive patients to 1:3 with chronic use)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults: Immediate release forms: 2-4 hours; Avinza&reg; ~24 hours;  Kadian&reg;:11-13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Avinza&reg;: 30 minutes (maintained for 24 hours); Kadian&reg;: ~10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily as morphine-3-glucuronide, ~2% to 12% excreted unchanged); feces (~7% to 10%). It has been suggested that accumulation of morphine-6-glucuronide might cause toxicity with renal insufficiency. All of the metabolites (ie, morphine-3-glucuronide, morphine-6-glucuronide, and normorphine) have been suggested as possible causes of neurotoxicity (eg, myoclonus).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Acute Pain Management in Infants, Children, and Adolescents: Operative and Medical Procedures. Agency for Health Care Policy and Research,&rdquo;",
"      <i>",
"       Am Fam Physician",
"      </i>",
"      , 1992, 46(2):469-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/1636563/pubmed\" id=\"1636563\" target=\"_blank\">",
"        1636563",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, \"2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(18):e426-579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/21444888/pubmed\" id=\"21444888\" target=\"_blank\">",
"        21444888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aubrun F, Mazoit JX, and Riou B, &ldquo;Postoperative Intravenous Morphine Titration,&rdquo;",
"      <i>",
"       Br J Anaesthesia",
"      </i>",
"      , 2012, 108(2):193-201.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/22250276/pubmed\" id=\"22250276\" target=\"_blank\">",
"        22250276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aubrun F, Monsel S, Langeron O, et al, &ldquo;Postoperative Titration of Intravenous Morphine in the Elderly Patient,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2002, 96(1):17-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/11752996/pubmed\" id=\"11752996\" target=\"_blank\">",
"        11752996",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(1):263-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/23269131/pubmed\" id=\"23269131\" target=\"_blank\">",
"        23269131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berde C, Ablin A, Glazer J, et al, &ldquo;American Academy of Pediatrics Report of the Subcommittee on Disease-Related Pain in Childhood Cancer,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(5 Pt 2):818-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/2216644/pubmed\" id=\"2216644\" target=\"_blank\">",
"        2216644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bril V, England J, Franklin GM, et al, \"Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2011, 76(20):1758-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/21482920/pubmed\" id=\"21482920\" target=\"_blank\">",
"        21482920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brunk SF and Delle M, &ldquo;Morphine Metabolism in Man,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1974, 16(1):51-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/4843237/pubmed\" id=\"4843237\" target=\"_blank\">",
"        4843237",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bujedo BM, \"A Clinical Approach to Neuroaxial Morphine for the Treatment of Postoperative Pain,\"",
"      <i>",
"       Pain Res Treat",
"      </i>",
"      , 2012, 8(3):177-92",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/23002426/pubmed\" id=\"23002426\" target=\"_blank\">",
"        23002426",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capogna G, Celleno D, Zangrillo A, et al, &ldquo;Addition of Clonidine to Epidural Morphine Enhances Postoperative Analgesia After Cesarean Delivery,&rdquo;",
"      <i>",
"       Reg Anesth",
"      </i>",
"      , 1995, 20(1):57-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/7727330/pubmed\" id=\"7727330\" target=\"_blank\">",
"        7727330",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chou R, Fanciullo GJ, Fine PG, et al, &ldquo;Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain,&rdquo;",
"      <i>",
"       J Pain",
"      </i>",
"      , 2009, 10(2):113-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/19187889/pubmed\" id=\"19187889\" target=\"_blank\">",
"        19187889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dampier CD, Setty BN, Logan J, et al, &ldquo;Intravenous Morphine Pharmacokinetics in Pediatric Patients With Sickle Cell Disease,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1995, 126(3):461-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/7869211/pubmed\" id=\"7869211\" target=\"_blank\">",
"        7869211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedrichsdorf SJ and Kang TI, &ldquo;The Management of Pain in Children With Life-Limiting Illness,&rdquo;",
"      <i>",
"       Pediatr Clin N Am",
"      </i>",
"      , 2007, 54(5):645-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/17933616/pubmed\" id=\"17933616\" target=\"_blank\">",
"        17933616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glare PA and Walsh TD, &ldquo;Clinical Pharmacokinetics of Morphine,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 1991, 13(1):1-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/2057987/pubmed\" id=\"2057987\" target=\"_blank\">",
"        2057987",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Golianu B, Krane EJ, Galloway KS, et al, &ldquo;Pediatric Acute Pain Management,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 2000, 47(3):559-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/10835991/pubmed\" id=\"10835991\" target=\"_blank\">",
"        10835991",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Henneberg SW, Hole P, Madsen de Haas I, et al, &ldquo;Epidural Morphine for Postoperative Pain Relief in Children,&rdquo;",
"      <i>",
"       Acta Anaesthesiol Scand",
"      </i>",
"      , 1993, 37(7):664-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/8249555/pubmed\" id=\"8249555\" target=\"_blank\">",
"        8249555",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holdsworth MT, Adams VR, Chavez CM, et al, &ldquo;Continuous Midazolam Infusion for the Management of Morphine-Induced Myoclonus,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(1):25-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/7711342/pubmed\" id=\"7711342\" target=\"_blank\">",
"        7711342",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practice (ISMP), &ldquo;Beware of Basal Opioid Infusions With PCA Therapy,&rdquo; 2009.  Available at https://www.ismp.org/Newsletters/acutecare/articles/20090312.asp",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, &ldquo;Standard Concentrations of Neonatal Drug Infusions,&rdquo; 2011.  Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      June HL, Stitzer ML, and Cone E, &ldquo;Acute Physical Dependence: Time Course and Relation to Human Plasma Morphine Concentrations,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57(3):270-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/7697945/pubmed\" id=\"7697945\" target=\"_blank\">",
"        7697945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaiko RF, &ldquo;Age and Morphine Analgesia in Cancer Patients With Postoperative Pain,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1980, 28(6):823-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/7438698/pubmed\" id=\"7438698\" target=\"_blank\">",
"        7438698",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lvovschi V, Aubrun F, Bonnet P, et al, &ldquo;Intravenous Morphine Titration to Treat Severe Pain in the ED,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 2008, 26(6):676-82.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meine TJ, Roe MT, Chen AY, et al, &ldquo;Association of Intravenous Morphine Use and Outcomes in Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement Initiative,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 2005, 149(6):1043-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/15976786/pubmed\" id=\"15976786\" target=\"_blank\">",
"        15976786",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McRorie TI, Lynn AM, Nespeca MK, et al, &ldquo;The Maturation of Morphine Clearance and Metabolism,&rdquo;",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1992, 147(8):972-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mignault GG, Latreille J, Viguie F, et al, &ldquo;Control of Cancer-Related Pain With MS Contin: A Comparison Between 12-Hourly and 8-Hourly Administration,&rdquo;",
"      <i>",
"       J Pain Symptom Manage",
"      </i>",
"      , 1995, 10(6):416-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/7561223/pubmed\" id=\"7561223\" target=\"_blank\">",
"        7561223",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olkkola KT, Hamunen K, and Maunuksela EL, &ldquo;Clinical Pharmacokinetics and Pharmacodynamics of Opioid Analgesics in Infants and Children,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1995, 28(5):385-404.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/7614777/pubmed\" id=\"7614777\" target=\"_blank\">",
"        7614777",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&rdquo; 6th ed, Glenview, IL: American Pain Society, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rathmell JP, Lair TR, and Nauman B, &ldquo;The Role of Intrathecal Drugs in the Treatment of Acute Pain,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2005, 101(5 Suppl):30-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/16334491/pubmed\" id=\"16334491\" target=\"_blank\">",
"        16334491",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rathmell JP, Viscomi CM, and Ashburn MA, &ldquo;Management of Nonobstetric Pain During Pregnancy and Lactation,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1997, 85(5):1074-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/9356103/pubmed\" id=\"9356103\" target=\"_blank\">",
"        9356103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spigset O and Hagg S, &ldquo;Analgesics and Breast-feeding: Safety Considerations,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2000, 2(3):223-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/10937472/pubmed\" id=\"10937472\" target=\"_blank\">",
"        10937472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sultan P, Gutierrez MC, and Carvalho B, &ldquo;Neuraxial Morphine and Respiratory Depression: Finding the Right Balance,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      ,  2011, 71(14):1807-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/21942973/pubmed\" id=\"21942973\" target=\"_blank\">",
"        21942973",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wunsch MJ, Stanard V, and Schnoll SH, &ldquo;Treatment of Pain in Pregnancy,&rdquo;",
"      <i>",
"       Clin J Pain",
"      </i>",
"      , 2003, 19(3):148-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/12792553/pubmed\" id=\"12792553\" target=\"_blank\">",
"        12792553",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zacher JL and Givone DM, &ldquo;False-Positive Urine Opiate Screening Associated With Fluoroquinolone Use,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2004, 38:1525-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/31/19962/abstract-text/15252190/pubmed\" id=\"15252190\" target=\"_blank\">",
"        15252190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9788 Version 57.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-DF771C1915-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_31_19962=[""].join("\n");
var outline_f19_31_19962=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775511\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776636\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776637\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776648\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776811\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776810\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776812\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776813\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776814\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776907\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776908\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776646\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776634\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9845085\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776887\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472937\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472938\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776767\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776698\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775520\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776723\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776704\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776705\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776734\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776735\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776739\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776699\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776700\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776702\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776703\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776886\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776910\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776892\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961991\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776768\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776772\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9788\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9788|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/33/14870?source=related_link\">",
"      Morphine sulfate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=related_link\">",
"      Morphine sulfate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_31_19963="Complementary therapies";
var content_f19_31_19963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complementary and alternative therapies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Acupuncture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ayurveda",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Biofeedback",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chelation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chiropractic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Energy healing/Reiki",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Folk medicine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Herbs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       High dose vitamins",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Homeopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypnosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Massage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Naturopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Qigong",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Relaxation techniques",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Special diets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tai Chi",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Yoga",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tindle HA, Davis RB, Phillips RS, Eisenberg DM. Trends in the use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med 2005; 11:42.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_31_19963=[""].join("\n");
var outline_f19_31_19963=null;
var title_f19_31_19964="Warfarin maintenance dose adjustment";
var content_f19_31_19964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F87435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F87435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Algorithm for adjustment of maintenance warfarin dosing based on the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) study",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"15%\">",
"     </colgroup>",
"     <colgroup width=\"85%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        INR",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adjustment in total mg of warfarin per week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &le;1.5",
"       </td>",
"       <td>",
"        Increase 15 percent per week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.51 to 1.99",
"       </td>",
"       <td>",
"        Increase 10 percent per week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 to 3",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3.01 to 4",
"       </td>",
"       <td>",
"        Decrease 10 percent per week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4.01 to 4.99",
"       </td>",
"       <td>",
"        Hold one dose; restart with dose decreased by 10 percent per week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5 to 8.99",
"       </td>",
"       <td>",
"        Hold until INR is 2 to 3; restart with dose decreased by 15 percent per week",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The table provides an algorithm for monitoring and adjustment of maintenance warfarin dosing with a goal of maintaining the INR between 2 and 3. This algorithm is not applicable to selecting a warfarin starting dose for warfarin na&iuml;ve patients or for adjusting the starting dose during the first week of warfarin treatment (refer to UpToDate topic on the use of warfarin for further information).",
"    <br>",
"     The maintenance dose algorithm requires that INR measurements are made at a maximum interval of every four weeks, with at least weekly monitoring for out of range INRs (&lt;2 or &gt;3).",
"     <br>",
"      All percent changes in warfarin dosage are adjusted based on the current INR value and calculated based upon the sum of the previous seven days of warfarin doses (also known as mg of warfarin per week). The increase or decrease in warfarin dose per week is distributed over the following week.",
"      <br>",
"       As an example, a patient taking 30 mg of warfarin per week with an INR of 1.8 would increase the dose by 10 percent (ie, 3 mg). The new weekly dose would be 33 mg, which could be distributed over the week as 5 mg daily on six days and 3 mg on the remaining day. Several alternate means of administering 33 mg per week could also be used, depending on which dose(s) of warfarin pills the patient had available. Based upon warfarin's mechanism of action, it is preferable to distribute doses as close to evenly as practical throughout the week.",
"       <div class=\"footnotes\">",
"        INR: international normalized ratio.",
"       </div>",
"       <div class=\"reference\">",
"        Data from: Van Spall HG, Wallentin L, Yusuf S, et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation (RE-LY) trial. Circulation 2012; 126:2309.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_31_19964=[""].join("\n");
var outline_f19_31_19964=null;
var title_f19_31_19965="Genes involved DSD B";
var content_f19_31_19965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genes known to be involved in disorders of sex development (DSD) (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Gene",
"      </td>",
"      <td class=\"subtitle1\">",
"       Protein",
"      </td>",
"      <td class=\"subtitle1\">",
"       OMIM No.",
"      </td>",
"      <td class=\"subtitle1\">",
"       Locus",
"      </td>",
"      <td class=\"subtitle1\">",
"       Inheritance",
"      </td>",
"      <td class=\"subtitle1\">",
"       Gonad",
"      </td>",
"      <td class=\"subtitle1\">",
"       Mullerian structures",
"      </td>",
"      <td class=\"subtitle1\">",
"       External genitalia",
"      </td>",
"      <td class=\"subtitle1\">",
"       Associated features/variant phenotypes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       46,XX DSD",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"9\">",
"       Disorders of gonadal (ovarian) development",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       SRY",
"      </td>",
"      <td>",
"       TF",
"      </td>",
"      <td>",
"       480000",
"      </td>",
"      <td>",
"       Yp11.3",
"      </td>",
"      <td>",
"       Translocation",
"      </td>",
"      <td>",
"       Testis or ovotestis",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       Male or ambiguous",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       SOX9",
"      </td>",
"      <td>",
"       TF",
"      </td>",
"      <td>",
"       608160",
"      </td>",
"      <td>",
"       17q24",
"      </td>",
"      <td>",
"       dup17q24",
"      </td>",
"      <td>",
"       Not determined",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       Male or ambiguous",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"9\">",
"       Androgen excess",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       HB2 HSD",
"      </td>",
"      <td>",
"       Enzyme",
"      </td>",
"      <td>",
"       201810",
"      </td>",
"      <td>",
"       1p13",
"      </td>",
"      <td>",
"       AR",
"      </td>",
"      <td>",
"       Ovary",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       Clitoromegaly",
"      </td>",
"      <td>",
"       CAH, primary adrenal failure, partial androgenization caused by dehydroepiandrosterone sulfate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       CYP21A2",
"      </td>",
"      <td>",
"       Enzyme",
"      </td>",
"      <td>",
"       201910",
"      </td>",
"      <td>",
"       6p21-23",
"      </td>",
"      <td>",
"       AR",
"      </td>",
"      <td>",
"       Ovary",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       Ambiguous",
"      </td>",
"      <td>",
"       CAH, phenotypic spectrum from severe salt-losing forms associated with adrenal failure to simple virilizing forms with compensated adrenal function, 17-hydroxyprogesterone",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       CYP11B1",
"      </td>",
"      <td>",
"       Enzyme",
"      </td>",
"      <td>",
"       202010",
"      </td>",
"      <td>",
"       8q21-22",
"      </td>",
"      <td>",
"       AR",
"      </td>",
"      <td>",
"       Ovary",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       Ambiguous",
"      </td>",
"      <td>",
"       CAH, hypertension caused by 11-deoxycortisol and 11-deoxycorticosterone",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       POR (P450 oxidoreductase)",
"      </td>",
"      <td>",
"       CYP enzyme electron donor",
"      </td>",
"      <td>",
"       124015",
"      </td>",
"      <td>",
"       7q11.2",
"      </td>",
"      <td>",
"       AR",
"      </td>",
"      <td>",
"       Ovary",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       Ambiguous",
"      </td>",
"      <td>",
"       Mixed features of 21-hydroxylase deficiency, 17 &alpha;-hydroxylase/17,20-lyase deficiency, and aromatase deficiency; associated with Antley Bixler craniosynostosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       CYP19",
"      </td>",
"      <td>",
"       Enzyme",
"      </td>",
"      <td>",
"       107910",
"      </td>",
"      <td>",
"       15q21",
"      </td>",
"      <td>",
"       AR",
"      </td>",
"      <td>",
"       Ovary",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       Ambiguous",
"      </td>",
"      <td>",
"       Maternal androgenization during pregnancy, absent breast development at puberty, except in partial cases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Glucocorticoid receptor",
"      </td>",
"      <td>",
"       Nuclear receptor TF",
"      </td>",
"      <td>",
"       138040",
"      </td>",
"      <td>",
"       5q31",
"      </td>",
"      <td>",
"       AR",
"      </td>",
"      <td>",
"       Ovary",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       Ambiguous",
"      </td>",
"      <td>",
"       Adrenocorticotropin, 17-hydroxyprogesterone and cortisol; failure of dexamethasone suppression (patient heterozygous for a mutation in CYP21)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Chromosomal rearrangements likely to include key genes are included.",
"    <div class=\"footnotes\">",
"     OMIM: Online Mendelian Inheritance in Man; TF: transcription factor; AD: autosomal dominant (often do novo mutation); AR: autosomal recessive; Y: Y-chromosomal; X: X-chromosomal.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lee PA, Houk CP, Ahmed SF, Hughes IA; International Consensus Conference on Intersex organized by the Lawson Wilkins Pediatric Endocrine Society and the European Society for Pediatric Endocrinology. Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. Pediatrics 2006; 118:e488. Copyright &copy; 2006 by the AAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_31_19965=[""].join("\n");
var outline_f19_31_19965=null;
var title_f19_31_19966="Phosphatidylinositol turnover";
var content_f19_31_19966=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F70144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F70144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phosphatidylinositol-protein kinase C pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 369px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the phosphatidylinositol pathway-protein kinase C pathway. The binding of a peptide hormone with its cell surface receptor (R) leads to activation of the associated stimulatory regulatory guanylyl protein (Gs) with a subsequent increase in activity of membrane-bound phospholipase C. This enzyme results in the breakdown of a membrane lipid, phosphatidylinositol 4,5-bisphosphate (PIP2), into two compounds: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 mediates the immediate action of the hormone by inducing the release of calcium from stores in the smooth endoplasmic reticulum; and indirectly by enhancing the uptake of extracellular calcium ion. The increased intracellular calcium binds to calmodulin leading to the phosphorylation and activation of specific cell proteins and the physiologic effects of the hormone. Among the proteins phosphorylated and activated, with the cooperation of DAG, is calcium-dependent protein kinase C which initiates a further cascade of protein phosphorylation that mediates the sustained physiologic action of the hormone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_31_19966=[""].join("\n");
var outline_f19_31_19966=null;
var title_f19_31_19967="Fat sol vit DRI";
var content_f19_31_19967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dietary reference intakes for fat-soluble vitamins",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Nutrient",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age group",
"       </td>",
"       <td class=\"subtitle1\">",
"        <span class=\"green\">",
"         RDA*",
"        </span>",
"        /",
"        <span class=\"red\">",
"         AI",
"         <sup>",
"          &bull;",
"         </sup>",
"        </span>",
"       </td>",
"       <td class=\"subtitle1\">",
"        UL",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adverse effects of excess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Vitamin A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"21\">",
"        1 mcg retinol activity eqivalent = 3.3 unit vitamin A",
"       </td>",
"       <td class=\"subtitle3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle3\">",
"        Micrograms daily",
"       </td>",
"       <td class=\"subtitle3\">",
"        Micrograms daily",
"       </td>",
"       <td rowspan=\"21\">",
"        Ataxia, alopecia, hyperlipidemia, hepatotoxicity, bone and muscle pain; teratogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        0-6 months",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"red\">",
"         400",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        7-12 months",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"red\">",
"         500",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 to 3 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"green\">",
"         300",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4 to 8 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"green\">",
"         400",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        900",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Males",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        9 to 13 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"green\">",
"         600",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        1700",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        14 to 18 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"green\">",
"         900",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        2800",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &ge;19 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"green\">",
"         900",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        3000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Females",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        9 to 13 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"green\">",
"         600",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        1700",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        14 to 18 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"green\">",
"         700",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        2800",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &ge;19 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"green\">",
"         700",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        3000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &lt;18 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"green\">",
"         750",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        2800",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &ge;19 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"green\">",
"         770",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        3000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Lactation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &lt;18 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"green\">",
"         1200",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        2800",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &ge;19 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"green\">",
"         1300",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        3000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Vitamin D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"12\">",
"        (calciferol) 1 mcg calciferol = 40 IU",
"       </td>",
"       <td class=\"subtitle3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle3\">",
"        Micrograms daily",
"       </td>",
"       <td class=\"subtitle3\">",
"        Micrograms daily",
"       </td>",
"       <td rowspan=\"12\">",
"        Hypercalcemia, hypercalciuria, polydipsia, polyuria, confusion, anorexia, vomiting, bone demineralization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" rowspan=\"2\">",
"        0 to 12 months",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"2\">",
"        <span class=\"red\">",
"         10 (400 IU)",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        0 to 6 months: 25 (1000 IU)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        6 to 12 months: 37.5 (1500 IU)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Children and adolescents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" rowspan=\"3\">",
"        1 to 18 years",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        <span style=\"color: #008000;\">",
"         15 (600 IU)",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 to 3 years: 62.5 (2500 IU)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        4 to 8 years: 75 (3000 IU)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        9 to 18 years: 100 (4000 IU)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Males and females (including pregnancy and lactation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        19 to 50 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span style=\"color: #008000;\">",
"         15 (600 IU)",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        100 (4000 IU)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        50 to 70 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span style=\"color: #008000;\">",
"         15",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &gt;70 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span style=\"color: #008000;\">",
"         20 (800 IU)",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Vitamin E",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"14\">",
"        <p>",
"         (alpha-tocopherol)",
"        </p>",
"        <p>",
"         1 mg = 1.47 IU \"natural source\" vitamin E, or 2.2 IU synthetic vitamin E",
"        </p>",
"       </td>",
"       <td class=\"subtitle3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle3\">",
"        Milligrams daily",
"       </td>",
"       <td class=\"subtitle3\">",
"        Milligrams daily",
"       </td>",
"       <td rowspan=\"14\">",
"        Increased risk of bleeding; possibly increased risk of necrotizing enterocolitis in infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        0-6 months",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"red\">",
"         4",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        7-12 months",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"red\">",
"         5",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 to 3 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"green\">",
"         6",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4 to 8 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"green\">",
"         7",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        300",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Males and females (including pregnancy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        9 to 13 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"green\">",
"         11",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        14 to 18 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"green\">",
"         15",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        800",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &gt;18 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"green\">",
"         15",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        1000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Lactation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &le;18 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"green\">",
"         19",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        800",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &gt;19 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"green\">",
"         19",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        1000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Vitamin K",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"15\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle3\">",
"        Micrograms daily",
"       </td>",
"       <td class=\"subtitle3\">",
"        Micrograms daily",
"       </td>",
"       <td rowspan=\"15\">",
"        No adverse effects associated with vitamin K consumption from food or supplements have been reported, however data are limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        0-6 months",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"red\">",
"         2",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        7-12 months",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"red\">",
"         2.5",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 to 3 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"red\">",
"         30",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4 to 8 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"red\">",
"         55",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Males",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        9 to 13 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"red\">",
"         60",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        14 to 18 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"red\">",
"         75",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &gt;19 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"red\">",
"         120",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Females (including pregnancy and lactation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        9 to 13 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"red\">",
"         60",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        14 to 18 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"red\">",
"         75",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &gt;19 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"red\">",
"         90",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        ND",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Vitamin A doses given as retinol activity equivalents (RAE). 1 RAE = 1 mcg retinol, 12 mcg beta-carotene, 14 mcg alpha-carotene, or 24 mcg beta-cryptoxanthin.",
"    <div class=\"footnotes\">",
"     <span style=\"color: #008000;\">",
"      RDA: recommended dietary allowance;",
"     </span>",
"     <span style=\"color: #ff0000;\">",
"      AI: adequate intake;",
"     </span>",
"     UL: upper tolerable level.",
"     <br/>",
"     * The RDA is the level of dietary intake that is sufficient to meet the daily nutrient requirements of 97 percent of the individuals in a specific life stage group.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     The AI represents an approximation of the average nutrient intake that sustains a defined nutritional state, based on observed or experimentally determined values in a defined population.",
"     <br/>",
"     &Delta; The UL is the maximum level of daily nutrient intake that is likely to pose no risk of adverse health effects in almost all individuals in the specified life-stage or gender group.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Dietary Reference Intake reports of the Food and Nutrition Board, Institute of Medicine. Available at:",
"     <a href=\"file://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Report-Brief.aspx\" target=\"_blank\">",
"      file://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Report-Brief.aspx",
"     </a>",
"     (Accessed on December 1, 2010).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_31_19967=[""].join("\n");
var outline_f19_31_19967=null;
